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ABSTRACT 
 
Prokaryotic fatty acid biosynthesis is an important process to study due to its necessity 
for cell survival and production of highly reduced carbon chains. A characterization of 
several proteins involved in E. coli fatty acid biosynthesis is presented. This work 
provides a method for generating large amounts of pure malonyl acyl-carrier-protein 
using both the wild type malonyl-CoA:holo-ACP transacylase (FabD) and a variant 
studied further in our lab. This preparation overcomes the phenomena of a 50:50 
mixture of malonyl and acetyl-ACP in the reaction and is crucial for the efficacy of future 
assays involving malonyl-ACP. A new assay has been developed to measure activity of 
the FabD enzyme using a fluorescent probe and can be scaled from a rapid to high 
throughput assay using 96 well plates. FabD variants were studied with the above 
assay and kinetic constants were determined for several different CoA substrates with 
enhanced chemical functionality. The structure of holo-ACP synthase in apo and acyl-
carrier-protein bound forms was investigated in depth using a combination of X-ray 
crystallography, NMR spectroscopy, and isothermal titration calorimetry. This work is a 
comprehensive study of the enzymes involved in the first steps of fatty acid biosynthesis 
using several biochemical and biophysical techniques.  
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CHAPTER 1: INTRODUCTION TO FATTY ACID BIOSYNTHESIS 
Type I and Type II FAS: 
Fatty acid biosynthesis is essential for the growth and development of all 
organisms from the simplest single celled prokaryotes to humans [1,2,3]. The two 
main classes of fatty acid synthase (FAS), Type I and Type II generate highly 
reduced carbon chain end products, but do so using either a single polypeptide 
mega-enzyme or a system made up of many individual enzymes, respectively 
[4]. Type I FAS is found in mammals and yeast and is made up of a single 
polypeptide with all of the enzymatic activities necessary to generate fatty acids 
localized onto a single scaffold. The shared single polypeptide structure of these 
two enzymes is met with a very different quaternary structure. Human FAS 
consists of a homodimer with two 250 kDa subunits, while yeast FAS is a 2.6 
MDa dodecamer. The yeast FAS has a α6β6 organization where one α and β 
component combined contain the eight activities necessary for fatty acid 
biosynthesis yielding six complete biosynthetic replicates in yeast [5]. Each of 
these Type I FAS systems have a tethered acyl-carrier protein (ACP) capable of 
reaching all of the different active site centers on the molecule [4,5,6]. This 
localization of all active sites onto one polypeptide could be a more efficient 
process of generating fatty acids, at the expense of synthesizing a very complex 
molecular machine. It should be noted, however, that replacing the yeast FAS 
with all of the components of E. coli FAS rescues this pathway and allows for 
growth of the organism [7]. The ability to replace Type I FAS with Type II 
suggests fatty acid synthesis necessity outweighs the manner in which they are 
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synthesized. This was a big step to breaking down the single polypeptide into its 
component parts and allowing for simplified engineering of each enzyme [7]. 
The groundwork into defining the Type II prokaryotic FAS began with the 
basic isolation and characterization of several enzymes from Escherichia coli 
[8,9,10,11,12]. The condensation reaction was particularly exciting being the first 
catalyzed by a biological system to be discovered [12]. This research set the 
stage for a more complete characterization of these enzymes and their 
respective activities and over the next 20-30 years these enzymes were studied 
in great detail [13,14,15,16]. The driving force for studying prokaryotic FAS was 
the promise of potential inhibitors of the pathway and novel antibiotics. The 
dissociated enzyme system is attractive to researchers as it provides unique 
motifs not found in the mammalian system [2]. Adverse effects of drugs targeting 
Type II FAS may be alleviated by the lacking structural relationship to Type I 
FAS. Drugs made to specifically target Type II FAS could be specific to that 
pathway and have few side effects in the human system. This key difference is 
what drives the research into not only understanding how the two systems work, 
but how one type can be exploited without having an effect on the other. 
Microbes and mammals have been discussed, but the plant FAS system 
resembles the Type II system [17]. This may be unexpected as higher order 
organisms like mammals use a Type I system, what is even more surprising is 
that unlike mammals and microbes that synthesize fatty acids in the cytoplasm or 
cytosol, plants make their fatty acids in an organelle (plastid)[17,18]. These fatty 
acids that are synthesized then need to be transported out of the plastid into the 
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cytoplasm to be activated into glycerophospholipids at the ER for making cell 
membranes [17]. This covers the most critical organisms and their methodology 
for synthesizing fatty acids, but it should be noted mitochondria also maintain 
their own FAS machinery and it resembles the Type II system [19]. Mitochondrial 
FAS functions with an entire suite of enzymes and its own soluble ACP as 
opposed to the tethered ACP of mammalian and yeast FAS. There is clear 
diversity in the ways each organism makes their fatty acids, and this is also 
evident in the types of fatty acids made and the use of these fatty acids.  
Fatty Acid use and incorporation: 
Fatty acids are utilized for the formation of cellular membranes, bacterial 
defense material (lipopolysaccharides), long term energy storage, and other 
purposes like plant waxes [18,20]. The first fundamental difference observed is 
the distribution of chain lengths and branching of the fatty acids. Plants have 
distinct distributions of fatty acids, an example is rapeseed has >50% C20-C22 
whereas maize, soybean, and safflower all have >50 % C18:2 and no C20-C22 
[21,22]. These defining characteristics are exploited every day in the food 
industry for cooking oils as well as in the use of biodiesel [22,23]. These distinct 
distributions set the stage for metabolic engineering around a suitable starting 
point of fatty acid content. Bacteria have distinct ranges of fatty acid content and 
the biggest difference can be observed when comparing thermophilic to non-
thermophilic bacteria. In one study it was shown that a thermophilic bacterium 
had an increased amount of short/medium chain (C12-C15) when compared to 
non-thermophilic that had a more traditional range of C16-C18[24]. The 
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thermophilic bacteria also have a greatly increased percentage of iso-branched 
fatty acids and little to no unsaturated fatty acids which aid in membrane stability 
and rigidity at high temperatures where the unsaturated fatty acids will be found 
in more temperate bacteria. E. coli generate mostly C16-C18 fatty acids, but 
interestingly show a marked decrease in C18 when growth is shifted from 30 °C 
to 45 °C. This decrease in longer chain fatty acids in E. coli at increased 
temperatures and in thermophiles is believed to help with membrane stability at 
increased temperatures and maintaining a liquid crystalline state [25,26].  
Fatty acid incorporation into membranes is possibly their most obvious 
and important use. Fatty acids are linked to a central glycerol molecule with the 
final product being a glycerophospholipid which is packaged into the 
phospholipid bilayer. These membranes are essential for life and help in 
determining a major branch point in evolution [27]. Early membrane synthesizing 
proteins can be found that used the limited fatty acids available to create the 
membranes and one from archaea was studied in detail [28]. The 
glycerophospholipids are necessary for creating the phospholipid bilayer 
separating two aqueous compartments and their contents from each other. In 
eukaryotes this separation is important as compartmentalization is critical to the 
efficacy of the organism. There are many membrane bound organelles each with 
their own biological role and they function best when separated. This separation 
provides a diffusion barrier as well as a more defined shape that can be 
necessary for certain organelles [29]. In prokaryotes these membranes are 
mostly for energy potential, but also provide a cellular defense mechanism. The 
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trans-membrane protein ATPase relies on a proton gradient to function in 
generating large amounts of ATP and without a membrane the formation of this 
gradient would not be feasible [30,31]. These fatty acids can also be used to 
make triacylglycerol molecules whose importance varies across the various 
forms of life, but is an excellent form of energy storage [32,33]. 
Fats in the form of triacylglycerols, wax esters, polyhydroxyalkanoates 
(bacteria only) are an important long term storage form of energy as they contain 
highly reduced carbon chains and can provide large amounts of energy to the 
cell when needed (Figure 1-1). In bacteria these fatty acids are broken down in 
the cytosol by the process of beta oxidation which yields one acetyl-CoA 
molecule for every 2 carbons in the fatty acid chain.  
Figure 1-1.  The three most common forms of reduced carbon chain energy 
storage for many organisms A. Polyhydroxyalkanoates. B. fatty acid wax esters C. 
triacylglycerol 
 
Beta oxidation provides cells with reducing factors and acetyl-CoA which all play 
an important role in driving central metabolism. The energy production from the 
oxidation of a C16 fatty acid provides 2.4 times more ATP than the complete 
breakdown of glucose by weight [34]. This shows the immense amount of energy 
stored in the fatty acids and why they make such a good storage form. When 
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fatty acids are packaged into triacylglycerols they are stored in a nearly 
anhydrous form allowing them to pack their total energy even more densely than 
proteins or sugars (glycogen) which are hydrated [32]. 
Lipopolysaccharides (LPS) are a fatty acid containing antigenic molecule. 
LPS plays a critical role in the antigenic mode of a bacterial capsule and gives 
gram negative bacteria their infectiousness. The first subunit of LPS is lipid A 
which consists of a lipid containing portion with six fatty acid chains connected to 
a disaccharide sugar, usually β(16)-linked D-glucosamine [35]. There is then a 
core oligosaccharide and an O-polysaccharide that are linked to the lipid A which 
can also have antigenic properties. The lipid A component of LPS is highly 
conserved among gram negative bacteria [20,35]. Lipid A anchors the LPS to the 
outer membrane, presenting the polysaccharides which act as a protective 
barrier and can also have some immune activating properties [35,36]. Fatty acids 
play a crucial role in the life of many organisms and function in numerous ways, 
this is evidenced by the great diversity evidenced above for these many 
incorporations of fatty acids. The enzymes involved in the early stages of 
transacylation and condensation are of interest in this work and will be detailed 
below. 
Enzymes of Interest: 
Holo-ACP Synthase (ACPS) is the first enzyme of interest in this 
dissertation as it primes the acyl carrier protein (ACP) with the 
phosphopantetheine moiety from Coenzyme A as shown in Figure 1-2. The 
ACPS enzyme has been expressed and purified from several organisms and in 
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all cases relies on a divalent cation such as magnesium for functionality 
[37,38,39,40,41]. This enzyme catalyzes a hydrolysis reaction where the 
coenzyme A molecule is cleaved at the phosphodiester bond leaving 3’,5’ 
adenosine diphosphate and phosphopantheine. After the hydrolysis, the hydroxyl 
group of serine 36 on ACP can perform a nucleophilic attack on the 
phosphopantethiene completing the catalytic cycle.  
 
Figure 1-2 E. coli fatty acid biosynthesis pathway high-lighting the key reactions 
with enzymes and substrates shown as crystal structure cartoon diagrams. 
At this point holo-ACP is ready for the next modification which primes it for the 
iterative condensation reactions. Holo-ACP is a soluble cytosolic protein in 
bacteria and plants, but in mammals and yeast it is tethered to the single 
polypeptide FAS and can access each active site pocket on the mega enzyme. 
There was debate within the literature about the oligomerization of the 
enzyme and its dependence on whether or not the organism was gram positive 
or negative [38]. For E. coli and Mycoplasma pneumoniae it was believed that it 
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formed a dimeric structure while in other organisms such as Bacillis subtillis it 
formed a trimeric structure [39,40]. This observation was even more intriguing as 
the crystal structure of the trimeric enzyme suggested that the only way to form 
three active sites was to have this axially symmetric trimer where residues from 
neighboring chains could provide substrate stabilization and catalytic function 
[40]. Work presented in this dissertation sheds some light on the interpretation of 
the data previously collected and provides solution and crystal data to definitely 
show oligomerization state of the E. coli holo-ACP Synthase. 
The next step in the pathway is the transfer of a malonate moiety from 
malonyl-CoA to holo-ACP catalyzed by the malonyl-CoA:ACP transacylase 
(FabD) enzyme. This is a critical reaction as malonyl-ACP is the key intermediate 
in growing the fatty acid chain two carbon units at a time. The reaction starts with 
the transfer of malonate from malonyl-CoA to the active site nucleophile Ser92 
on E. coli FabD. Following this transfer and the release of CoA, the 
phosphopantetheine on holo-ACP will enter the active site and the free thiol on 
holo-ACP is modified with the malonate group. At this point malonyl-ACP will 
serve as the condensing substrate for all subsequent rounds of condensation in 
fatty acid biosynthesis and this makes it a critical intermediate in fatty acid 
biosynthesis and FabD an essential enzyme [42]. FabD has been crystallized 
many times from many different organisms leading to significant knowledge 
about substrate binding and active site chemistry [41,43,44,45,46,47,48,49]. 
These numerous structural studies show the highly conserved fold and 
organization of the enzyme active site. There is a distinct catalytic dyad 
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consisting of the active site nucleophile (ser92) and the catalytic base his201. 
These two residues are critical to enzyme function[50], but there are several 
other amino acid side chains pointing into the active site that are involved in 
substrate stabilization and pocket formation. These amino acids are arginine 117, 
glutamine 11, and glutamine 250. Glutamine 11 functions to stabilize the 
malonate-enzyme intermediate while also hydrogen bonding with arginine 117 
which stabilizes the distal carboxylate of the malonate moiety through a salt 
bridge and is consequently stabilized itself by glutamine 250 and another 
hydrogen bond[48]. While the aforementioned residues act to stabilize the active 
site there are also conserved residues that form non covalent stabilizing 
interactions with the adenine nucleotide portion of malonyl-CoA. 
The β-ketoacyl synthase III (FabH) enzyme functions next in the fatty acid 
biosynthesis pathway. This enzyme performs an ordered ping pong reaction in 
the same way that the FabD enzyme does, but uses cysteine as its active site 
nucleophile instead of serine [13,51]. Similarly to FabD, FabH first binds its CoA 
substrate (acetyl-CoA) and transfers the acetate moiety from acetyl-CoA to the 
cysteine 112 in the active site. This reaction is facilitated by the active site base 
histidine 244 which activates the cysteine by absconding its proton [52]. The 
FabH-acetate intermediate is stabilized by the formation of an oxyanion hole 
consisting of backbone amides on cysteine 112 and glycine 306 [52]. Following 
acetate transfer the malonyl modified phosphopantetheine of malonyl-ACP 
enters the active site, the terminal carboxylate is decarboxylated, and the 
resulting carbanion can perform nucleophilic attack on the carbonyl carbon of the 
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acetate-enzyme intermediate. This concludes the catalytic event and leaves the 
final acetoacetyl-ACP product. This reaction is also catalyzed by KASI and KASII 
enzymes where the priming substrate is an acyl-ACP and not acetyl-CoA, but still 
utilize malonyl-ACP as the condensing unit [53]. One of the interesting 
characteristics of FabH is that unlike the KASI and KASII enzymes it functions 
with a CoA and ACP based substrate where the former enzymes utilize two ACP 
based substrates. This would suggest alternative substrate recognition on the 
surface of the proteins in the context of similar active site chemistry and 
substrate binding. 
There are three enzymes that work to fully reduce the second keto group 
on acetoacetyl-CoA to an alkane. They are the reductase (FabG), a dehydratase, 
and a final enoyl-ACP reductase. FabG uses NADPH to reduce the keto group to 
an alcohol [54]. The NADPH utilization has made the FabG enzyme useful for 
linked enzyme assays coupling condensing or transacylase enzymes to the 
NADPH dependent FabG reaction [55]. After the keto group is reduced to an 
alcohol the alcohol is removed by the dehydratase enzyme (FabZ) [56,57]. This 
dehydration leaves a 2-enoyl product which must be reduced a final time to yield 
the fully saturated acyl chain that can be further elongated by more condensation 
reactions. This final reduction reaction is catalyzed by the enoyl-ACP reductase 
enzyme (FabI) which can act on numerous acyl chain length substrates [58]. The 
FabI chemistry is extremely interesting, first NADH or NADPH donates a proton 
to the distal side of the double bond leaving a carbanion on what was the 
proximal side of the double bond, then this carbanion can abstract a proton from 
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a tyrosine active site residue [59]. The tyrosine hydroxyl has a pka of ~10 making 
it a potential proton donor in the context of an enzyme active site. At this point 
the fully reduced acyl chain is prepared for iterative condensations, reductions 
and dehydrations. 
 There has been significant effort into metabolic engineering of plants, 
yeast, and bacteria to select for the overproduction of fatty acids or molecules 
from the fatty acid pathway [60,61]. Large volume growth of organisms and their 
many metabolites that can be applied to everyday petrochemical supplements 
makes them a focus of study. To this point there have been very few engineering 
attempts involving the enzymes studied in this work and others involved in fatty 
acid biosynthesis with the exception of thioesterases from various organisms with 
altered substrate specificity [62]. The KASIII enzyme has been mutated to allow 
for increased acyl-CoA substrate plasticity by mutations at residue 87 [61]. These 
mutations of a phenylalanine to either tryptophan or threonine allowed for 
increased formation of polyhydroxyalkanoates in bacteria [63]. Overexpression of 
FabH leads to the accumulation of shorter chain fatty acids [13,61], a promising 
step in purifying useable fatty acids and allowing for the conversion by 
esterification or decarboxylation. The FabD enzyme has not been studied using 
mutagenesis for engineering, but has been overexpressed in E. coli and the 
resulting fatty acid pool analyzed. These studies showed that overexpression of 
the FabD enzyme increases the total amount of fatty acids in the cell [64]. This 
type of study lends merit to the motivation of mutating FabD to accept non 
canonical substrates and using that enzyme in an organism. The limited 
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mutagenesis and basic functional studies necessitates the structural and 
functional characterization of these enzymes with an overall focus on 
downstream metabolic engineering, regulatory effects, and potential inhibitor 
design. 
Fatty acid biosynthesis is critical to the proliferation of all forms of life, but 
its products are also of interest due to their application to biorenewable resources 
[65,66,67]. Highly reduced carbon chains provide products or intermediates that 
resemble important molecules derived from fossil fuel sources. Short to medium 
chain fatty acids would provide drop in replacements for fuels while long chain 
fatty acids can be used to supplement oils and lubricants. Biorenewable sources 
of diacids such as adipic acid can be implemented into nylon production [68]. 
This dissertation will discuss our efforts to analyze the structure and function of 
enzymes and enzyme variants that have enhanced substrate recognition 
capabilities. We also investigated the structure of these enzymes and determined 
how substrate recognition can be manipulated to allow for less stringent 
substrate specificity. 
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Highlights: 
1. We demonstrate the lab-scale production of holo-ACP and malonyl-ACP to 
high titers 
2. The ACP and ACP synthase polypeptides form a discrete oligomer 
3. The beta-ketoacyl synthase FabH efficiently utilizes our malonyl-ACP 
preparation 
4.  We describe a fluorescence-based assay to monitor FabH activity  
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Abstract 
The fatty acid biosynthetic pathway generates highly reduced carbon based 
molecules. For this reason fatty acid synthesis a target of pathway engineering to 
produce novel specialty or commodity chemicals using renewable techniques to 
supplant molecules currently derived from petroleum. Malonyl-[acyl carrier 
protein] (malonyl-ACP) is a key metabolite in the fatty acid pathway and donates 
two carbon units to the growing fatty acid chain during each step of biosynthesis. 
Attempts to test engineered fatty acid biosynthesis enzymes in vitro will require 
malonyl-ACP or malonyl-ACP analogs. Malonyl-ACP is challenging to prepare 
due to the instability of the carboxylate leaving group and the multiple steps of 
post-translational modification required to activate ACP. Here we report the 
expression and purification of holo- and malonyl-ACP from Escherichia coli with 
high yields (>15 mg per L of expression). The malonyl-ACP is efficiently 
recognized by the E. coli keto-acylsynthase enzyme, FabH. A FabH assay using 
malonyl-ACP and a coumarin-based fluorescent reagent is described that 
provides a high throughput alternative to reported radioactive assays. 
 
Introduction 
The promise of biorenewable chemicals for the chemical industry extends 
beyond replacing the petroleum source of contemporary chemical precursors and 
reaches towards developing new molecules with alternative functionalization and 
structure [1]. To achieve this goal, enzymes, biosynthetic pathways, and 
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microorganisms must be engineered to synthesize alternative substrates. One 
fundamental barrier to progress is preparing appropriate substrates, many of 
which are protein-bound intermediates and thus challenging synthetic targets. 
 Fatty acid biosynthesis (FAS) is one pathway targeted for engineering [2]. 
Prokaryotic fatty acid biosynthesis employs a dissociated multi-polypeptide 
system that allows for the targeting of individual enzymes, unlike eukaryotic FAS 
which uses a fused system [3]. The products of the pathway are long chain 
hydrocarbons that have significant commercial value. The Escherichia coli FAS 
machinery can be manipulated into producing free fatty acids [4]. It has also been 
demonstrated that varying fatty acid chain length can be selected for in E. coli 
variants [5]. Alternative, shorter compounds can be produced by truncating the 
pathway and will serve as novel starting points to prepare a wide range of 
compounds. It is widely believed that the pathways may be engineered for the 
production of custom molecules [6-8]  
 E. coli β-keto-acylsynthase III (FabH) catalyzes the Claisen-condensation 
of malonyl-ACP and acetyl-coenzyme A (acetyl-CoA) as the priming step of fatty 
acid biosynthesis (Figure 2-1) [9]. This reaction yields the four carbon 
acetoacetyl-ACP product which serves as the substrate for two NADH/NADPH-
dependent reduction steps, generating butyryl-ACP that can be extended in a 
malonyl-ACP dependent reaction by the keto-acylsynthase I or II enzymes [10]. 
In vitro examination of this system requires high titers of malonyl-ACP. 
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Figure 2-1. An excerpt from the fatty acid biosynthesis pathway highlights 
the steps of ACP modification. ACP and its various modified forms are 
highlighted. The enzymes that catalyze these reactions are indicated in bold. 
 
 Malonyl-ACP is challenging to prepare for multiple reasons, the first of 
which is that holo-ACP is required as a substrate (Fig 2-1) [11]. Holo-ACP is 
formed by the transfer of phosphopantetheine from CoA to serine 36 of apo-ACP, 
the unmodified polypeptide [12, 13]. This reaction can be performed on the 
benchtop or in vivo with overexpression of the holo-ACP synthase gene [11]. 
Malonyl-ACP is then formed by the transfer of the malonyl moiety from malonyl-
CoA to holo-ACP and is catalyzed by the malonly-CoA:ACP transacylase, FabD 
[14, 15]. Once prepared, malonyl-ACP spontaneously decarboxylates to form 
acetyl-ACP. 
 We developed a strategy to prepare holo-ACP by coexpressing apo-ACP 
and holo-ACP synthase in E. coli with a pETDueTTM (EMD Millipore) vector. This 
system allows for a simplified expression system that provides post-translational 
modification in situ. Because malonyl-ACP is labile, we developed a strategy to 
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modify holo-ACP in vitro. The combination of improved expression techniques 
and a high-throughput fluorescence based assay will allow for facile modification 
of the ACP or malonyl-CoA donor to probe engineered enzymes in vitro.  
 
Materials and Methods 
Materials- All materials were purchased from Sigma-Aldrich unless noted 
otherwise. All buffers were made with double distilled water. 
 Expression and purification of holo-ACP- Holo-ACP was expressed in E. 
coli BL21* DE3 cells harboring a pETDuetTM-vector (EMD-Millipore) containing 
the apo-ACP and holo-ACP synthase genes under control of individual T7 
promoters. Apo-ACP was cloned into BamHI and EcoRI of the first multiple 
cloning site (MCS) while holo-ACP synthase was inserted into the NdeI and XhoI 
restriction sites in the second MCS of the pETDuetTM vector. The holo-ACP 
expression cassette is designed to include a 6xHis tag at the N-terminus and the 
holo-ACP synthase cassette includes no modifications. E. coli cells were 
transformed with the protein expression vector and grown to mid log phase 
(OD600=0.5) at 37 °C in a shaking incubator (Thermo Scientific MaxQ 4000) and 
induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). At the 
moment of induction, temperature was reduced to 18 °C. After 16-18 hours cells 
were pelleted and resuspended in 25 mL lysis buffer (20 mM 
Tris(hydroxymethyl)aminomethane (TRIS), 500 mM sodium chloride, 1 mM 2-
mercaptoethanol pH=8.1). The cell suspension was then passed through an 
Emulsiflex C5 homogenizer (Avestin) five times at 15000 psi. Cell debris was 
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removed from the lysate by centrifugation at 14000 rpm for 1 h in a Fisher 
Scientific Sorvall Legend XTR centrifuge operating at 4 °C. The clarified lysate 
(CL) was applied to a 5 mL nickel-NTA column (Qiagen) pre-equilibrated with 
lysis buffer. The flow through (FT) was collected and set aside on ice. The 
column was washed with 25 mL of the base buffer 20 mM TRIS, 500 mM sodium 
chloride, 1 mM 2-mercaptoethanol, pH 8.1 (W1), then washed again with 25 mL 
of the base buffer plus 30 mM imidazole (W2), followed by 25 mL of the base 
buffer plus 50 mM imidazole (W3). Protein was eluted in three 5 mL fractions with 
a buffer consisting of the base buffer plus 100 mM imidazole, followed by three 5 
mL fractions with the base buffer plus 250 mM imidazole. Fractions were 
analyzed by SDS-PAGE by loading 2.5 µl of each elution and wash fraction onto 
a 20% SDS PAGE gel. 
 Fractions containing holo-ACP were pooled and diluted to a final salt 
concentration of 50 mM and loaded onto a 2.6 cm diameter column containing 
150 mL Q-Sepharose Fast Flow resin (GE healthcare). A two buffer system was 
employed to wash and run the column. Buffer A consisted of 25 mM 3-
morpholinopropane-1-sulfonic acid (MOPS), 1 mM 2-mercaptoethanol, pH 7.1. 
Buffer B was buffer A plus 1M potassium chloride, pH 7.1. All buffers were made 
with a filter sterilized stock of MOPS buffer. The Q-column was loaded at a flow 
rate of 2 mL/min and then washed at the same flow rate with 50 mL of Buffer A, 
followed by elution with a 200 mL linear gradient from 200-600 mM potassium 
chloride by adjusting the ratio of A/B. The column was then washed with 25 mL 
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Buffer B, then 200 mL Buffer A. Fractions (8 mL) were collected and analyzed by 
SDS-PAGE.   
 Determining the amount of free thiol on holo-ACP-  Purified holo-ACP (~10 
mg) was concentrated to 500 µL using a 3 kDa MWCO Amicon centrifugal filter 
unit and then passed over a 5 mL G25 column equilibrated with 20 mM Tris-HCl, 
100 mM NaCl, pH 7.5 to remove DTT. Fractions containing ACP were pooled 
and the volume reduced to 1 mL.  
An aliquot of the ACP sample (50 µL) was added to a 950 µl solution 
containing 100 mM Tris-HCL and 200 µM 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB), pH 7.5. After a 30 min incubation at RT, absorbency at 412 nM was 
measured using a quartz cuvette and a Varian, Inc. Cary® 50 UV-Vis 
spectrophotometer. A similar reaction with 50 µL of the G25 equilibration buffer 
added to the 950 µL reaction mix listed above served as a blank for the A412 
measurements. Each reaction was performed in triplicate. Similar assays were 
performed on control reactions that included the loading of only DTT on the G25 
column. These results indicated that DTT and ACP eluted in resolved, non-
overlapping peaks and DTT did not contaminate the ACP fractions. 
Another aliquot was analyzed by 1H NMR. The NMR sample (600 µL) 
consisted of 229.87 µL ACP, 5% D2O, 200 µM DSS, 25 mM MOPS, 100 mM 
NaCl, 1 mM DTT, pH 7.0. The signals from five resolved methyl peaks upfield of 
the bulk protein signal were integrated and compared to the internal DSS 
standard to determine protein concentration using an 18.8T Bruker instrument 
equipped with an AvanceIII console and a 5 mm cryoprobe. 
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Expression and Purification of FabD and FabH: The genes encoding FabH 
and FabD were inserted into the pET29a and pET28b expression vectors (EMD 
Millipore) respectively. The constructs were unmodified and contained no tags. 
The expression was conducted as described above for holo-ACP. The FabH 
clarified lysate was applied to the 150 mL Q-Sepharose column and washed with 
50 mL of a 100 mM sodium phosphate, 1 mM 2-mercaptoethanol, pH 7.0 buffer, 
followed by a linear gradient from 0-500 mM potassium chloride using same 
buffer, supplemented with 1 M potassium chloride. The column was then washed 
with 25 mL of the 1M potassium chloride buffer followed by 200 mL of the 
phosphate buffer with no potassium chloride. Fractions containing FabH as 
determined by SDS-PAGE were concentrated to ~5 mL using a 10kDa-cutoff 
Amicon filter (EMD) and applied to a 600 mm Superdex 200 column with a 
diameter of 26 mm (GE Healthcare). The S200 Column was run at a flow rate of 
0.5 mL/min. Buffer used was 100 mM sodium phosphate and 1 mM dithiothreitol. 
The fractions containing FabH were concentrated and stored in 50% glycerol. 
The procedure for purifying FabD was the same as FabH, but the Q-column 
buffers consisted of 25 mM MOPS in place of sodium phosphate. The S200 
buffer for FabD contained 25 mM MOPS, 100 mM sodium chloride, and 1 mM 
dithiothreitol. 
Malonyl-ACP Preparation: Malonyl-ACP was prepared in a reaction 
containing 90 µM holo-ACP, 2.25 mM malonyl-CoA, 6 µM FabD, 25 mM MOPS, 
100 mM sodium chloride, and 1 mM dithiothreitol, pH 7.1 in a final volume of 4 ml 
and incubated for 16-20 hours at 0 °C. Complete conversion to malonyl-ACP was 
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verified by MALDI-TOF MS using a Voyager-DE Pro MALDI-TOF instrument 
(Applied Biosystems). The spotting conditions were as follows: protein was 
diluted to ~10 µg/µL in DI water, this was then mixed 1 µL:1 µL in alpha-Cyano-4-
hydroxycinnamic acid (ACH), and one µL was spotted on a JBI 100 well MALDI 
plate. Following conversion, malonyl-ACP was adsorbed onto a 1 ml nickel-NTA 
column (Qiagen). Reaction components were removed by extensively washing 
the column with a buffer containing 25 mM MOPS, 500 mM sodium chloride, 1 
mM dithiothreitol, pH 7.1. Malonyl-ACP was eluted with the same buffer 
containing 25 mM MOPS, 500 mM sodium chloride, 1 mM dithiothreitol, and 30, 
50 or 250 mM imidazole. Fractions containing malonyl-ACP were concentrated 
and exchanged into a buffer containing 25 mM MOPS, 100 mM sodium chloride, 
pH 7.1 using a 3 kDa-cutoff centrifugal filter device as described above. Protein 
was then diluted with glycerol to a final concentration of 10-25% (v/v) and 500 µM 
malonyl-ACP and stored at -80 °C. 
 FabH Activity Assays: A fluorometric assay was adapted [16] to monitor 
the appearance of CoA via a reaction of a fluorescent reagent 7-diethylamino-3-
(4-maleimidophenyl)-4-methylcoumarin (CPM) with the newly formed CoA thiol. 
The FabH assay was conducted with 50 µM acetyl-CoA, 50 µM malonyl-ACP (or 
malonyl-CoA), 100 mM phosphate buffer, pH 7.0, at 30 °C in a volume of 100 µl. 
FabH concentrations ranged from 0.5-5 µM for the reactions with malonyl-CoA 
and 1-25 nM for the reactions with malonyl-ACP. Six 10 µl aliquots were removed 
from the reaction at various times and quenched with 190 µl of 10 µM CPM in 
100% DMSO solution. Fluorescence was measured with excitation at 384 nm 
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and emission at 470 nm using a Cary Eclipse fluorimeter. The fluorimeter was 
calibrated using a standard curve of CoA in the quench solution. 
Size exclusion chromatography of holo-ACP- Fractions containing holo-
ACP from the Q-column were concentrated to 2-5 mL using a 3 kDa molecular 
weight cutoff centrifugal filter device (EMD Millipore) and loaded onto a 475 mm 
Superdex 75 (S75; GE Healthcare) column with a diameter of 26 mm. The 
column was washed with 25 mM MOPS, 100 mM sodium chloride, and 1 mM 
dithiothreitol. The column was run with a flow rate of 0.5 mL / min using the same 
buffer and 3.5 ml fractions were collected. SDS PAGE was used to analyze the 
fractions. Fractions containing holo-ACP were concentrated to <1 mL and diluted 
with glycerol to a final concentration of 25% (v/v) and stored at -80 °C. 
 
Results and Discussion 
Expression and identification of a stable complex 
We developed a method that permits simultaneous expression of the ACP 
polypeptide and holo-ACP synthase enzyme in E. coli to facilitate recovery of 
holo-ACP. The ability to prepare ACP with a high percentage in the holo- form 
eliminates the need to separate holo-ACP and apo-ACP for downstream 
analysis. Furthermore, this coexpression method saves an additional step of 
CoA-dependent apo-ACP conversion in vitro.  
ACP from the E. coli cell lysate was purified using an immobilized metal 
ion affinity column as shown in Figure 2-2.  
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Figure 2-2. Purification of a holo-ACP:holo-ACP synthase complex using 
immobilized metal ion affinity chromatography.“Pre” and “post” refers to 
samples of bacteria harvested at the time of IPTG addition or at the end of the 
culture, respectively. “CL” refers to the lysate following centrifugation, and “FT” is 
the lysate following passage over the column. Washes “W” and elutions “E” are 
as described. 
 
ACP eluted at the same position as the coexpressed holo-ACP-synthase. 
MALDI-TOF MS analysis revealed that a high percentage of the ACP pool was 
modified with a phosphopantetheine moiety.  
The ACP and holo-ACP synthase proteins were not separated by a S-75 
size exclusion column. Although a very small amount of ACP eluted as a 
monomer from a gel-filtration column, the predominate pool of ACP eluted much 
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earlier and at the same time as the holo-ACP synthase as shown in Figure 2-3. 
 
Figure 2-3. Size exclusion chromatography of the ACP:holo-ACP synthase 
complex. (A) Profiles of absorbency at 280 nm (solid line) and conductivity 
(dashed line) are shown from the purification using a Superdex S200 column. (B) 
Calibration curve for the S200 column using proteins of known mass. 
 
ACP and holo-ACP synthase appeared to form a multimer that was stable and 
eluted in a single, sharp peak at a volume of 200 mL that corresponds to a 
molecular weight of 95.1 kDa (Figure 2-3) [17, 18]. This is a surprise because the 
masses of holo-ACP and holo-ACP synthase are 10.6 kDa and 13.9 kDa, 
respectively, though the E. coli holo-ACP synthase purifies as a homodimer [19]. 
It appears, based on the SDS-PAGE analysis that ACP and holo-ACP synthase 
elute with 1:1 stoichiometry. The molecular weights, stoichiometry, and dimer 
model for one partner suggest formation of a 4:4 heterooctamer with a theoretical 
molecular mass of 97.4 kDa. This predicted mass is only 2.5% greater than the 
observed mass of the ACP:holo-ACP synthase complex. Because estimates of 
molecular weight using gel filtration chromatography are sensitive to the shape of 
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the analyte, it is formally possible that the complex may also be either a 1:1 
heterodimer, 2:2 heterotetramer or 3:3 heterohexamer. 
The formation of a discrete multimeric complex is likely important for holo-
ACP synthase function. It is important to note that the abundance of apo, holo, 
and acetyl-ACP in the complex is similar to the abundance of these forms in the 
free ACP that eluted much later from the column (data not shown). This is not 
surprising as E. coli holo-ACP synthase can utilize both CoA and acetyl-CoA with 
comparable efficiencies [19]. 
Separation of ACP and holo-ACP synthase 
Initial attempts to disrupt the ACP-holo-ACP synthase complex with a size 
exclusion chromatography step at neutral, high or low pH, increased salt 
concentration, or metal ion affinity chromatography following incubation with 6M 
urea were largely unsuccessful. 
Anion exchange chromatography was utilized, in lieu of the size exclusion 
chromatography step, to achieve the separation following a linear salt gradient as 
shown in Figure 2-4.  
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Figure 2-4. ACP is efficiently separated from holo-ACP synthase using 
anion exchange chromatography. (A) Profiles of absorbency at 280 nm (solid 
line) and conductivity (dashed line) are shown from purification using an anion 
exchange column. (B) SDS PAGE analysis of the fractions using a 20% 
acrylamide gel. Fraction numbers corresponding to the column purification are 
indicated. 
The fractions containing holo-ACP synthase (8-18) contained only holo-ACP 
synthase and no ACP as shown in Figure 2-5. Fractions 27-31 and contained 15 
mg of holo and acetyl-ACP (Table 1), but not holo-ACP synthase and are 
analyzed in Figure 2-6A.  A portion of the holo-ACP pool shows the characteristic 
shift of 177 mass units, indicating the presence of His6-tag gluconoylation [20, 
21]. 
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Figure 2-5. Analysis of holo-ACP synthase by mass spectrometry. 
A MALDI-TOF spectrum of the holo-ACP-synthase following anion exchange 
purification. Three peaks shown for the synthase correspond to the +2H+, +3H+ 
and +4H+ forms.  
 
We pursued a chemical method to measure the degree of 
phosphopantetheine modification in the holo-ACP preparation using natural 
features of apo and holo-ACP because the MALDI-MS based method does not 
provide an accurate quantification. Phosphopantetheinylation catalyzed by the 
holo-ACP synthase introduces a free thiol to holo-ACP that is not present in apo-
ACP which also contains no cysteine residues. Thus, a measurement of the free 
thiol content in a holo-ACP prep using the thiol-reactive reagent DTNB divided by 
the protein concentration as measured with NMR is expected to provide the 
percentage of phosphopantetheinylation that is accessible to further modification 
by FabD, the malonyl-CoA:ACP transferase. We determined that a sample 
containing 1.000 ± 0.083 molar equivalents of ACP polypeptide reacted with 
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0.800 ± 0.029 molar equivalents of DTNB. This result indicates that 80.0 ± 5.8% 
of the ACP pool contains a free thiol. 
Conversion to malonyl-ACP 
 Malonyl-ACP is formed in a malonyl-CoA dependent reaction catalyzed by 
the malonyl-CoA:ACP transacylase FabD. Purified E. coli FabD efficiently 
converted holo-ACP to malonyl-ACP as shown in Figure 2-6B.  
 
Figure 2-6. FabD efficiently converts holo-ACP to malonyl-ACP.(A) MALDI-
TOF analysis of ACP fractions after anion exchange chromatography.(B) A 
MALDI-TOF spectrum following the FabD-catalyzed conversion of holo-ACP to 
malonyl-ACP. The (+2H+) ions are shown in each panel. 
 
This reaction was performed at 0°C to prevent spontaneous decarboxylation, 
which occurs rapidly at higher temperatures. Previous techniques to monitor 
malonyl-ACP involve conformational sensitive gel electrophoresis [10]. This 
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method provided insufficient resolution of holo and malonyl-ACP in our 
laboratory, so we optimized an existing MALDI-TOF method for high sensitivity 
detection [22]. 
 It is curious to note that the levels of acetyl-ACP decrease during the 
reaction. E. coli FabD failed to catalyze a reaction with either acetyl-ACP or 
acetyl-CoA, suggesting a minor component in the reaction was responsible for 
depleting the acetyl-ACP pool. This unexpected side reaction was repeatable, 
and beneficial as it removed a contaminant to the malonyl-ACP preparation and 
occurred in a CoA dependent-manner. The acetyltransferase activity was 
removed from the ACP preparation by size exclusion chromatography using a 
Superdex 75 column (Figure 2-7). 
 
Figure 2-7. ACP elutes in a single peak from a Superdex75 size exclusion 
column. (A) Profiles of absorbency at 280 nm (solid line) and conductivity 
(dashed line) are shown. (B) SDS PAGE analysis of the S75 fractions using a 
20% acrylamide gel. Fraction numbers corresponding to the column purification 
are indicated. 
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 Following conversion to malonyl-ACP, reaction components are removed 
with a final metal affinity chromatography step using a 1 mL nickel column. 
Malonyl-ACP elutes in the 250 mM imidazole fractions. In total, 15 mg of 
malonyl-ACP was recovered from 1 L of E. coli expression (Table 2-1). 
Table 2-1. Purification and preparation of malonyl-ACP from a 1 L E. coli 
expression.  
 
 
 
 
Enzymatic analysis of malonyl-ACP 
Malonyl-ACP is a viable substrate for the enzyme FabH as shown by a 
fluorometric assay that traps the product CoA using the fluorescent coumarin-
based reagent, CPM (Figure 2-8) [16]. Furthermore, the initial reaction velocity 
increased linearly with respect to FabH concentration (Fig 2-8B). The assay used 
is an alternative to the reported radioactivity-based assays and we observed a 
FabH reaction rate of specific activity of 1 µmole CoA mg-1 FabH min-1. 
Radioactive assays for FabH monitoring [2-14C] malonyl-ACP production have 
shown a specific activity of 3 µmoles CoA mg-1 FabH min-1 [9]. 
Stage total protein (mg) 
Clarified 
Lysate 
206 
Nickel Column 62 
Q Column 15 
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Figure 2-8. FabH efficiently utilizes malonyl-ACP. (A) The accumulation of 
CoA is plotted for various reactions with FabH, acetyl-CoA, and malonyl-ACP. 
Only early portions of the reaction are shown. (B) The rate of CoA formation 
increases linearly (dotted line) with FabH concentration using acetyl-CoA and 
malonyl-ACP as substrates. The result shown is representative of multiple, 
independent experiments. 
 
Conclusion 
Here we demonstrate a complete strategy for holo- and malonyl-ACP production 
and characterization. Through co-expression with a modifying enzyme, holo-ACP 
was prepared with a single protein expression step followed by a rapid two-step 
column purification. High yields of malonyl-ACP were prepared following a single 
in vitro enzymatic conversion. The utility of these reagents to probe the enzymes 
of fatty acid biosynthesis was also presented and the fluorescent method 
reported serves as a viable alternative to radioactive assays. This expression 
and purification strategy is amenable to modifications, particularly with respect to 
alterations at the malonyl moiety because the FabD-catalyzed CoA-ACP thiol 
exchange is the final step in the process. This work provides new and accessible 
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tools to probe fatty acid biosynthesis and substrates for enzymes designed as 
green catalysts for the renewable production of commodity or specialty 
chemicals. 
Acknowledgements 
We thank Prof. Basil Nikolau, Dr. Bruce Fulton, Dr. Ganesh P. Subedi and Dr. 
Uzma I. Zakai at ISU for their assistance with this project. This material is based 
upon work supported by the National Science Foundation under Award No. EEC-
0813570, by funds from the Roy J. Carver Department of Biochemistry, 
Biophysics & Molecular Biology, the Center for Metabolic Biology, and the 
Laurence H. Baker Center for Bioinformatics & Biological Statistics at Iowa State 
University. Any opinions, findings, and conclusions or recommendations 
expressed in this material are those of the author(s) and do not necessarily 
reflect the views of the National Science Foundation.  
38 
 
Works Cited 
[1] B.J. Nikolau, M.A. Perera, L. Brachova, B. Shanks, Platform biochemicals for 
a biorenewable chemical industry. Plant J 54 (2008) 536-545. 
[2] J.W. Campbell, J.E. Cronan, Jr., Bacterial fatty acid biosynthesis: targets for 
antibacterial drug discovery. Annu Rev Microbiol 55 (2001) 305-332. 
[3] S.J. Wakil, J.K. Stoops, V.C. Joshi, Fatty acid synthesis and its regulation. 
Annu Rev Biochem 52 (1983) 537-579. 
[4] P. Xu, Q. Gu, W. Wang, L. Wong, A.G. Bower, C.H. Collins, M.A. Koffas, 
Modular optimization of multi-gene pathways for fatty acids production in E. 
coli. Nat Commun 4 (2013) 1409. 
[5] H. Wu, K.Y. San, Engineering Escherichia coli for odd straight medium chain 
free fatty acid production. Appl Microbiol Biotechnol 98 (2014) 8145-8154. 
[6] J.L. Blatti, J. Michaud, M.D. Burkart, Engineering fatty acid biosynthesis in 
microalgae for sustainable biodiesel. Curr Opin Chem Biol 17 (2013) 496-505. 
[7] T.P. Howard, S. Middelhaufe, K. Moore, C. Edner, D.M. Kolak, G.N. Taylor, 
D.A. Parker, R. Lee, N. Smirnoff, S.J. Aves, J. Love, Synthesis of customized 
petroleum-replica fuel molecules by targeted modification of free fatty acid 
pools in Escherichia coli. Proc Natl Acad Sci U S A 110 (2013) 7636-7641. 
[8] C. Khosla, J.D. Keasling, Metabolic engineering for drug discovery and 
development. Nat Rev Drug Discov 2 (2003) 1019-1025. 
[9] R.J. Heath, C.O. Rock, Inhibition of beta-ketoacyl-acyl carrier protein 
synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J Biol 
Chem 271 (1996) 10996-11000. 
[10] R.J. Heath, C.O. Rock, Enoyl-acyl carrier protein reductase (fabI) plays a 
determinant role in completing cycles of fatty acid elongation in Escherichia 
coli. J Biol Chem 270 (1995) 26538-26542. 
[11] Y. Liu, Y. Feng, Y. Wang, X. Li, X. Cao, S. Xue, Structural and 
biochemical characterization of MCAT from photosynthetic microorganism 
Synechocystis sp. PCC 6803 reveal its stepwise catalytic mechanism. 
Biochem Biophys Res Commun (2015). 
[12] J. Elovson, P.R. Vagelos, Acyl carrier protein. X. Acyl carrier protein 
synthetase. J Biol Chem 243 (1968) 3603-3611. 
[13] R.S. Flugel, Y. Hwangbo, R.H. Lambalot, J.E. Cronan, Jr., C.T. Walsh, 
Holo-(acyl carrier protein) synthase and phosphopantetheinyl transfer in 
Escherichia coli. J Biol Chem 275 (2000) 959-968. 
[14] F.E. Ruch, P.R. Vagelos, Characterization of a malonyl-enzyme 
intermediate and identification of the malonyl binding site in malonyl 
coenzyme A-acyl carrier protein transacylase of Escherichia coli. J Biol Chem 
248 (1973) 8095-8106. 
[15] C. Oefner, H. Schulz, A. D'Arcy, G.E. Dale, Mapping the active site of 
Escherichia coli malonyl-CoA-acyl carrier protein transacylase (FabD) by 
protein crystallography. Acta Crystallogr D Biol Crystallogr 62 (2006) 613-618. 
[16] C.C. Chung, K. Ohwaki, J.E. Schneeweis, E. Stec, J.P. Varnerin, P.N. 
Goudreau, A. Chang, J. Cassaday, L. Yang, T. Yamakawa, O. Kornienko, P. 
Hodder, J. Inglese, M. Ferrer, B. Strulovici, J. Kusunoki, M.R. Tota, T. Takagi, 
39 
 
A fluorescence-based thiol quantification assay for ultra-high-throughput 
screening for inhibitors of coenzyme A production. Assay Drug Dev Technol 6 
(2008) 361-374. 
[17] A.W. Barb, Intramolecular N-Glycan/Polypeptide Interactions Observed at 
Multiple N-Glycan Remodeling Steps through [(13)C,(15)N]-N-
Acetylglucosamine Labeling of Immunoglobulin G1. Biochemistry 54 (2015) 
313-322. 
[18] G.P. Subedi, Q.M. Hanson, A.W. Barb, Restricted motion of the conserved 
immunoglobulin G1 N-glycan is essential for efficient FcgammaRIIIa binding. 
Structure 22 (2014) 1478-1488. 
[19] K.A. McAllister, R.B. Peery, G. Zhao, Acyl carrier protein synthases from 
gram-negative, gram-positive, and atypical bacterial species: Biochemical and 
structural properties and physiological implications. J Bacteriol 188 (2006) 
4737-4748. 
[20] K.F. Geoghegan, H.B. Dixon, P.J. Rosner, L.R. Hoth, A.J. Lanzetti, K.A. 
Borzilleri, E.S. Marr, L.H. Pezzullo, L.B. Martin, P.K. LeMotte, A.S. McColl, 
A.V. Kamath, J.G. Stroh, Spontaneous alpha-N-6-phosphogluconoylation of a 
"His tag" in Escherichia coli: the cause of extra mass of 258 or 178 Da in 
fusion proteins. Anal Biochem 267 (1999) 169-184. 
[21] J.C. Aon, R.J. Caimi, A.H. Taylor, Q. Lu, F. Oluboyede, J. Dally, M.D. 
Kessler, J.J. Kerrigan, T.S. Lewis, L.A. Wysocki, P.S. Patel, Suppressing 
posttranslational gluconoylation of heterologous proteins by metabolic 
engineering of Escherichia coli. Appl Environ Microbiol 74 (2008) 950-958. 
[22] S. Lin, J.E. Cronan, The BioC O-methyltransferase catalyzes methyl 
esterification of malonyl-acyl carrier protein, an essential step in biotin 
synthesis. J Biol Chem 287 (2012) 37010-37020. 
 
 
40 
 
CHAPTER 3:  A RAPID FLUOROMETRIC ASSAY FOR THE S-
MALONYLTRANSACYLASE FABD AND OTHER  
SULFHYDRYL UTILIZING ENZYMES 
 
Aaron M. Marcella, Adam W. Barb 
Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology 
2437 Pammel Drive 
Molecular Biology Building, rm 4210 
Iowa State University, Ames, IA 50011 
A paper in the Journal of Biological Methods 
 
Running Title: 
Fluorometric assay for fatty acid biosynthesis 
 
Abbreviations: 
Fatty acid synthase (FAS), ketoacyl synthase III (FabH), malonyl-Coenzyme A 
transacylase (FabD), coenzyme A (CoA-SH), acyl carrier protein (ACP), 3-
morpholinopropane-1-sulfonic acid (MOPS), ethylenediaminetetraacetic acid 
(EDTA), 2-mercaptoethanol (BME), dithiothreitol (DTT), trichloroacetic acid 
(TCA), 7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin (CPM), Luria-
Bertani (LB) 
  
41 
 
Abstract 
The development of biorenewable chemicals will support green chemistry 
initiatives and supplement the catalog of starting materials available to the 
chemical industry. Bacterial fatty acid biosynthesis is being pursued as a source 
of protein catalysts to synthesize novel reduced carbon molecules in 
fermentation systems. The availability of methods to measure enzyme catalysis 
for native and engineered enzymes from this pathway remains a bottleneck 
because a simple quantitative enzyme assay for numerous enzymes doesn’t 
exist. Here we present two variations of a fluorescence assay that is readily 
extendable to high-throughput screening and is appropriate for thiol consuming 
and generating enzymes including the Escherichia coli enzymes malonyl-
coenzyme A transacylase (FabD) and keto-acylsynthase III (FabH). We 
measured KM values of 60 ± 20 µM (acetyl-CoA) and 30 ± 10 µM (malonyl-ACP) 
and a kcat of 7.4 - 9.0 s-1 with FabH. Assays of FabD included a precipitation step 
to remove the thiol-containing substrate holo-ACP from the reaction product 
coenzyme-A to estimate reaction rates. Analysis of saturation kinetics revealed 
KM values of 60 ± 20 µM (malonyl-CoA) and 40 ± 10 µM (holo-ACP) and a kcat of 
2100 - 2600 s-1for the FabD enzyme. Our data show similar results when 
compared to existing radioactive and continuous coupled assays in terms of 
sensitivity while providing the benefit of simplicity, scalability and repeatability. 
Fluorescence detection also eliminates the need for radioactive substrates 
traditionally used to assay these enzymes.  
Introduction 
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 Fatty acid biosynthesis produces reduced hydrocarbon chains and is a 
target of engineering efforts to develop novel routes to biorenewable chemicals 
[1]. Prokaryotic fatty acid biosynthesis is well characterized and a popular target 
for drop-in enzyme replacements due to implementation as a one-
polypeptide/one-activity system unlike eukaryotic synthases that are expressed 
as a single fused polypeptide and likely more challenging to engineer [2,3,4]. 
Biorenewable chemicals are increasingly being produced in fermentative 
systems (ethanol, arachidonic acid, docosahexaenoic acid, short and medium 
chain fatty acids and others [5,6,7] and future needs will likely be met by 
recombinant microbes that express engineered enzymes and secrete novel 
materials.  
Fatty acid biosynthesis builds a carbon chain on acyl carrier protein (ACP) 
two carbon units at a time. Acetyl-coenzyme A (acetyl-CoA) donates the two 
acetate carbons to prime the chain and the first reaction with malonyl-ACP 
generates acetoacetyl-ACP, carbon dioxide and CoA-SH. Acetoacetyl-ACP is 
reduced to butyryl-ACP and extended again using malonyl-ACP as the source of 
material. This extension/reduction cycle continues until the chain is cleaved from 
the acyl carrier protein or transferred directly to a lipid molecule. 
Enzymes that generate carbon-carbon bonds, including the keto-
acylsynthases (KAS), and enzymes that generate primers and extender units 
utilized by the keto-acylsynthases are of particular interest for biorenewable 
production. The β-ketoacyl-ACP synthase III (FabH) catalyzes the first priming in 
Escherichia coli fatty acid biosynthesis as shown in Figure 3-1.  
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Figure 3-1. Reactions catalyzed by FabH and FabD. 
A. FabH creates an acetyl-enzyme covalent intermediate at C112, releasing 
CoA-SH. Nucleophilic attack of the acetate by the decarboxylated malonyl-ACP 
forms acetoacetyl-ACP.  
B. FabD catalysis begins with the generation of a covalent intermediate at S92. 
This releases CoA-SH and allows for holo-ACP to attack the malonate 
intermediate on FabD creating malonyl-ACP.  
 
In fatty acid biosynthesis, the malonyl-CoA:ACP transacylase (FabD) 
generates the extender units by transferring the malonyl moiety from malonyl-
CoA to holo-ACP, forming the free thiol form of CoA (CoA-SH) and malonyl-ACP 
as shown in Figure 3-1. The result is zero net change in free thiol concentration 
and is not amenable to thiol reactive enzyme assays unless the two compounds 
could be separated. Diversification of substrate recognition by FabD would be 
required to modify the extender units incorporated during chain elongation. 
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In vitro strategies to screen and characterize designed enzymes requires 
an enzyme assay that is applicable to many of the diverse fatty acid biosynthesis 
enzymes, including FabD and FabH, and capable of high throughput to 
thoroughly analyze numerous target substrates and enzyme variants. Sulfhydryl 
containing compounds including CoA-SH and holo-acyl carrier protein (holo-
ACP) are utilized during biosynthesis and represent one common feature of 
many fatty acid biosynthesis enzymes that is detectable with high sensitivity in 
high throughput assays [11,12]. To date, the most common method of assessing 
enzyme activity for fatty acid biosynthesis enzymes involves radioactivity. While 
sensitive, these approaches are neither high throughput nor easily scalable 
[13,14,15,16]. Linked assays are also reported, but are neither easily adaptable 
to other enzymes in the pathway and [17] suffer from contaminants in the 
commercial enzyme preps (data not shown). 
Here we describe a fluorescence-based strategy that can function with 
numerous enzymes in the FAS pathway including FabH and FabD at high 
sensitivity and is applicable to high throughput screening. Common 
implementations of thiol reactive reagents require a net thiol change which is 
problematic for detecting FabD activity through a liberated thiol as noted above 
[11]. We incorporated a facile step to separate CoA-SH from holo-ACP with 
reproducible and quantitative yields (Figure 3-2). 
45 
 
 
Figure 3-2. Flow diagram for the FabH and FabD assays. Both reactions utilize 
the reaction of CoA-SH with CPM to quantify product formation in the final step. 
The FabD assay differs because holo-ACP must be removed.  
 
Free thiols, generated from the reaction cycle, are detected with 7-
diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM) [18]. This 
detection strategy is applicable to multiple enzymes and has proven to be reliable 
and sensitive [11,12].  
  
Materials and Methods 
All materials were purchased from Sigma Aldrich unless otherwise noted. 
FabD Preparation. The open reading frame for the Escherichia coli FabD gene 
was cloned into pET28b using the NcoI and EcoRI sites. This cloning strategy 
adds only an extra glycine at the N-terminal of the enzyme and does not utilize 
the N or C-terminal poly-histidine tags available in the vector sequence. The 
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EcFabD pET28b vector was transformed into E. coli BL21* DE3 cells and a 
single colony was selected then grown overnight in a 5 mL Luria-Bertani (LB) 
culture with 50 μg/mL kanamycin. This culture was then added to 1 l LB with 50 
μg/mL kanamycin and grown to mid log phase (OD600~0.5) at 37 °C in a shaking 
incubator (Thermo Scientific MaxQ 4000). At this time fresh Isopropyl β-D-1-
thiogalactopyranoside was added to a final concentration of 0.5 mM and 
incubated with shaking for approximately 18 hours at 18 °C. Cells were then 
pelleted by centrifugation and resuspended in 30 mL lysis buffer (25 mM MOPS, 
1 mM EDTA, 1 mM BME, pH 7.1). The cell resuspension was lysed in an 
Emulsiflex C5 homogenizer (Avestin) five times at 12000 psi and the lysed cell 
debris pelleted at 24500 rcf in a Fisher Scientific Sorvall Legend XTR centrifuge 
for one hour. The clarified lysate was applied to a 110 mL Q-sepharose column 
(GE life sciences) and purified using two anion exchange buffers, A (lysis buffer) 
and B, lysis buffer supplemented with 1 M potassium chloride.  The column was 
washed with 0.5 column volume (CV) of buffer A followed by a linear gradient 
from 5-50% buffer B over one column volume. The column was washed with 0.2 
CV of 100% buffer B and finally 1.2 CV of 100% buffer A. Fractions were 
collected from the start of the gradient until the end of the run and the FabD 
enzyme elutes at ~30 % B.  
 Following anion exchange chromatography the fractions containing FabD 
were concentrated using a 10 kDa cutoff amicon ultracentrifugation filter unit 
(EMD Millipore) and applied to a Superdex S200 column (GE) equilibrated with 
25 mM MOPS, 100 mM sodium chloride, 1 mM DTT, pH 7.1. Fractions 
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containing FabD were concentrated as above and stored in 50 % glycerol at -80 
°C. FabD was quantified using the absorbance at 280 nm and an extinction 
coefficient of 32680 M-1cm-1. 
 
FabH Preparation. FabH was purified using anion exchange chromatography as 
described previously [11]. The two buffers used were buffer A: 20 mM 
phosphate, 1 mM EDTA, 5 mM BME pH 7.0 and buffer B which is buffer A with 1 
M potassium chloride. For FabH a linear gradient of buffer B was applied to the 
anion exchange column in the same manner as FabD. Following anion exchange 
chromatography the fractions containing FabH were pooled and applied to a blue 
sepharose column (GE) and a linear gradient of buffer B was used in the same 
way as the anion exchange step. Fractions containing FabH from the blue 
sepharose column were pooled and concentrated with a 10 kDa amicon filter and 
applied to an S200 column (GE). The S200 column was equilibrated and eluted 
with a buffer containing 20 mM phosphate, 50 mM KCl, 1 mM DTT, pH 7.0. 
Fractions containing FabH were pooled, concentrated as above and stored at 4 
°C. The FabH extinction coefficient used for quantification was 25690 M-1cm-1. 
 
Holo-ACP Preparation. Expression and purification of holo-ACP has been 
described previously [11]. Briefly, the acyl-carrier-protein and holo-(acyl-carrier-
protein) synthase genes were cloned into a pETDUET vector (EMD-Millipore). 
Both proteins were expressed simultaneously following the same steps as FabD 
expression (above). After lysing and centrifuging the cells the clarified lysate was 
48 
 
applied to an 8 mL nickel column (Qiagen) and an imidazole gradient was run 
from 0-500 mM imidazole in buffers containing 20 mM Tris-HCl, 500 mM sodium 
chloride, pH 8.1. Fractions containing holo-ACP were diluted to reduce sodium 
chloride to 100 mM and loaded onto a 110 mL Q-Sepharose column. A linear 
gradient from 200-600 mM potassium chloride was applied to the column and the 
holo-ACP eluted around 500 mM potassium chloride. Fractions containing ACP 
were concentrated and exchanged into a buffer containing 25 mM MOPS, 100 
mM sodium chloride, 1 mM DTT, pH 7.1 using a Superdex S75 column (GE). 
Fractions containing holo-ACP were concentrated using a 3 kDa amicon filter unit 
and stored at -80 °C in 10% glycerol. The ACP extinction coefficient used for 
quantification was 1490 M-1cm-1. 
 
Malonyl-ACP Preparation. Malonyl-ACP for the FabH assays was prepared as 
described previously [11]. Briefly, malonyl-CoA and holo-ACP were combined at 
a 25:1 (mole:mole) ratio with 5 µM FabD in 5 mL of 25 mM MOPS, 100 mM 
sodium chloride, and 1 mM DTT, pH 7.0. After 5 hours at 0 °C the reaction was 
applied to a 1 mL nickel column. The column was washed 2x (5 mL each wash) 
with a buffer containing 20 mM Tris-HCl, 500 mM sodium chloride, pH 8.1, and 
eluted with 5x 1 mL aliquots of the above buffer supplemented with 250 mM 
imidazole. Fractions containing Malonyl-ACP were pooled concentrated and 
exchanged into a buffer containing 25 mM MOPS, 100 mM sodium chloride, pH 
7.1, using an Amicon-Ultra 15 mL 3 kDa MWCO filter unit and stored at -80 °C 
following addition of glycerol to 10% v/v. The proportion of malonyl-ACP in the 
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total ACP pool was estimated at 40% using MALDI-TOF analysis, major 
contaminants include acetyl-ACP and holo-ACP (data not shown). 
 
The FabD Assay (See Figure 3-2): 
Reagents: 
o Wash buffer (25 mM MOPS, 100 mM sodium chloride, pH 7.1) 
o Assay buffer (25 mM MOPS, 100 mM sodium chloride, 1 mg/mL 
BSA, pH 7.1) 
o FabD Quench solution 1 (150 % w/v TCA) 
o FabD Quench solution 2 (95 % w/v TCA) 
o 1 mM CoA-SH 
o 100 µM CoA-SH 
o 3 mM holo-ACP 
o 10 mM malonyl-CoA 
o 1 nM FabD 
o 3.75 M Tris-HCl (pH 8.6) 
o 100 % DMSO 
o 10 mM CPM in DMSO 
o Neutralization solution (3.125 M Tris-HCl, 16.6 % DMSO, 50 µM 
CPM, pH 8.6) 
 
1. Exchange FabD and holo-ACP into 25 mM MOPS, 100 mM sodium 
chloride, pH 7.1 buffer to reduce the concentration of DTT by about 1000 fold.  
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2. Conduct assays in 200 or 800 µl volumes depending on the total 
amount of ACP or malonyl-CoA in the assay, the higher reaction volume is 
needed to increase sensitivity for assays with low substrate concentrations.  
3. An example 200 µl reaction is prepared with 4.7 µl 3 mM holo-ACP (70 
µM final), 20 µl 1 nM FabD enzyme (100 pM), with assays being brought to final 
volume (196 µl) with 171.3 µl assay buffer in a 1.5 mL tube.  
4. Place reactions in a 30 °C heat block to warm for 1 minute. Start assays 
with 4 µl of 10 mM malonyl-CoA (200 µM final). 
5. Aliquots (20 µl) are taken at intervals of 10 s for 1 min. Aliquots are 
immediately placed into FabD quench solution 1 then incubated on ice for five 
minutes (for 800 µl reactions, quench 80 µl into 40 µl FabD quench solution 2 
and place on ice). Quenched reactions are centrifuged at 16000 xg in a 
microcentrifuge at 4 °C for 15 minutes to pellet the protein. 
6. Draw off the supernatant (20 µl) and pipette into a 96 well dark sided 
plate with clear bottom (ThermoFisher).  50 µl of the neutralization solution is 
added to the plates and mixed thoroughly. It is critical to use enough Tris-HCl to 
ensure proper buffering of the reaction solution and complete reaction with the 
CPM reagent. This can be verified by applying ~1 µl of neutralized reaction to pH 
paper.  
7. Read plates in a plate reader (Tecan Safire) with an excitation 
wavelength of 380 nm and emission at 470 nm. Rates of product accumulation 
are fitted with a line over the linear portion of the assays using MS-Excel. Fits of 
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the Michaelis-Menten equation were performed using DynaFit 
(www.biokin.com/dynafit/). 
8. Make a standard curve using assay buffer and CoA-SH. For the 200 µl 
volume assays, mix 20 µl CoA-SH solution in reaction buffer with 10 µl FabD 
quench solution 1, place on ice for 15 minutes, and then centrifuge at 16000 xg 
and 4 °C. Neutralize 20 µl of the quenched standard curve solution with 50 µl 
neutralization solution. This yields a final volume for fluorescence analysis of 70 
µl, the same as for the assay. Concentrations of CoA-SH in the 20 µl samples 
are as follows: 0 µM, 2.625 µM, 5.25 µM, 10.5 µM, 26.25 µM, and 52.5 µM. This 
standard curve is used to calculate the concentration of CoA-SH produced in the 
assays. 
 
The FabH Assay: 
 FabH assays were conducted similarly to FabD, but the precipitation step 
is not required because only one thiol is generated (CoA-SH) and none are 
consumed.  
Reagents: 
o Wash buffer (20 mM phosphate, 50 mM potassium chloride, pH 
7.0) 
o Assay buffer (20 mM phosphate, 50 mM potassium chloride, 1 
mg/mL BSA, pH 7.0) 
o FabH Quench solution (50 µM CPM in DMSO) 
o 1 mM acetyl-CoA 
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o 2 mM malonyl-ACP 
o 100 nM FabH 
1. Exchange FabH into wash buffer to reduce the DTT concentration at 
least 1000x.  
2. Perform assays at 30 °C in 100 µl volumes with 7.5 µl, 1 mM mM 
acetyl-CoA (75 µM), 3.5 µl, 2 mM malonyl-ACP (70 µM), and 79 µl assay buffer.  
3. Start reactions with 10 µl of 100 nM FabH (10 nM). Aliquots were taken 
at 1, 2,4,6,8, and 10 min. At each time point 10 µl of the assay was removed from 
the reaction vessel then immediately quenched into 90 µl quench solution in a 96 
well plate. The samples were read in a Tecan Safire plate reader with excitation 
wavelength of 380 nm and emission at 470 nm. 
 
Results and Discussion 
We demonstrated the measurement of FabH activity using the described 
method and found reproducible rate measurements with minimal noise as shown 
in Figure 3-3A and B. Reactions without enzyme repeatedly showed flat profiles 
with zero slope (data not shown).  
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Figure 3-3. Saturation kinetics experiments for E. coli FabH. 
A. Progress curves for FabH reactions with varying concentrations of acetyl-CoA 
and 80 µM malonyl-ACP. B. Progress curves of FabH reactions with varying 
concentrations of malonyl-ACP and 200 µM acetyl-CoA. C. A plot of reaction 
rates versus acetyl-CoA concentration. D. A plot of reaction rates versus 
malonyl-ACP concentration. Dashed lines represent a linear fit to product 
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accumulation data and solid lines represent a fit of the Michaelis-Menten 
equation. 
 
Each experiment collected product accumulation data from 6 separate reactions 
resulting in 36 individual measurements that required one person about 45 min to 
complete from start to finish.  
To obtain estimates of Michaelis constants (KM) for each substrate as well 
as catalytic rates (kcat), one substrate was held at a concentration ~4 fold higher 
than its KM while the other substrate was varied. We fit the Michaelis-Menten 
equation to plots of the initial velocities versus the varied substrate concentration 
to estimate KM (acetyl CoA 60 ± 20 µM; malonyl-ACP 30 ± 10 µM) and kcat (7.4 ± 
0.8 s-1 and 9 ± 2 s-1, respectively). Data in Figure 3-3C and D show an overlay 
from two independent experiments collected on two different days. These data 
are shown in the raw form and individual experiments were not scaled for 
comparison which clearly demonstrates the high degree of repeatability and 
stability of the assay. Table 3-1 shows the resulting values measured using this 
method are comparable to previously measured values. 
The assay of FabH activity proved sensitive due to the generation of a free 
thiol (in the form of CoA-SH) during the reaction cycle. Assays of FabD activity 
could not use the same experimental approach because though a free thiol is 
generated (CoA-SH) during the reaction, one is consumed (holo-ACP) resulting 
in no net change in measurable CPM fluorescence (Figure 3-1). We developed a 
method that selectively precipitated the substrate holo-ACP from the reaction 
55 
 
mixture, leaving the product CoA-SH in solution. This solution could then be 
probed for free thiol content using the CPM reagent. 
Table 3-1. FabH kinetic data 
 
 
 
Reference 
 
 
 
Organism 
 
Mal-
ACP KM 
(μM) 
 
Acetyl-
CoA KM 
(μM) 
  
 
kcat1 (s-1)* 
 
 
kcat 2 (s-1)** 
This study E. coli 30 ± 10 60 ± 20 9.0 ± 2.0 7.4 ± 0.8 
Heath et al. [13] E. coli 5  40   n.r.  n.r. 
Qiu et al. [25] S. aureus 19 ± 7 373 ± 17  261 ± 34  431 ± 113 
Khandekar et al. 
[26] 
S. 
pneumoniae 
18.6 ± 
1.5  
40.3 ± 
2.3  
n.r.  n.r. 
*kcat1: measured with 75 µM malonyl-ACP and saturating acetyl-CoA  
**kcat2: measured with 250 µM acetyl-CoA and saturating malonyl-ACP 
n.r. = data not reported 
 
The FabD activity assay likewise proved sensitive and repeatable. Initially, 
multiple assays were conducted to determine optimal enzyme and substrate 
concentrations for saturation kinetics experiments (data not shown). Once 
conditions were identified, product accumulation was measured as shown in 
Figure 3-4 A and B.  
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Figure 3-4. Saturation kinetics experiments for E. coli FabD. 
A. Progress curves for FabD reactions with varying concentrations of malonyl-
CoA and 125 µM holo-ACP. B. Progress curves of FabD reactions with varying 
concentrations of holo-ACP and 250 µM acetyl-CoA. C. A plot of reaction rates 
versus malonyl-CoA concentration. D. A plot of reaction rates versus holo-ACP 
concentration. Dashed lines represent a linear fit to product accumulation data 
and solid lines represent a fit of the Michaelis-Menten equation. 
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Linearity over time is evident across all substrate concentrations assayed with 
only minor noise present at the lower substrate concentrations. Furthermore, 
observed reaction rates reached saturation at high substrate concentrations and 
permitted KM and kcat estimation by fitting the Michaelis-Menten equation as 
shown in Figure 3-4C and D. Data in Figure 3-4C and D show an overlay from 
three independent experiments collected on three different days. Similar to that 
observed for FabH, these data are shown in the raw form and individual 
experiments were not scaled for comparison which clearly demonstrates the high 
degree of repeatability and stability of the assay. Based on these analyses we 
estimated KM values of 40 ± 10 µM for holo-ACP and 60 ± 20 µM for malonyl-
CoA. Values for kcat, measured from each saturation curve, closely agreed at 
2600 ± 300 s-1 and 2100 ± 200 s-1. The comparison of the values reported herein 
closely agree with previously reported values shown in Table 3-2 [17,19,20,21]. 
Table 3-2. FabD kinetic data 
 
 
 
 
Reference 
 
 
 
 
Organism 
 
 
Holo-
ACP KM 
(μM) 
 
 
Malonyl-
CoA KM 
(μM) 
  
 
 
 
kcat1 (s-1)** 
 
 
 
 
kcat 2 (s-1)*** 
This study E. coli 40 ± 10 60 ± 20 2600 ± 300 2100 ± 200 
Molnos et al. [17] E. coli 19 25  n.r.  n.r. 
Joshi et al. [19] E. coli 54 25  n.r.  n.r. 
Szfranska et al. [20] S. coelicolor 73 60 450  n.r. 
Kremer et al. [21] M. tuberculosis 14 50*  n.r.  n.r. 
* Refit of published data with non-linear least squares fitting software 
(reported 12.6 µM) 
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** kcat1: measured with 250 µM malonyl-CoA and saturating holo-ACP 
*** kcat2: measured with 125 µM holo-ACP and saturating malonyl-CoA 
n.r. = data not reported 
 
FabD assays required care to ensure complete precipitation of holo-ACP 
during the quench step. Multiple TCA concentrations were tested and it should 
be noted that at excessive TCA concentration, holo-ACP initially precipitated but 
was subsequently hydrolyzed into soluble peptides that led to higher than 
expected CPM fluorescence. This was evident by the appearance and, within 
minutes, the disappearance of a white fluffy precipitate. ACP hydrolysis can be 
controlled by carefully tuning the TCA concentration for each different aliquot 
volume. For 20 µL aliquots, 10 µL 150% w/v TCA provided superior results but 
80 µL aliquots required 40 µL 90% w/v TCA. It also proved important to check 
the final pH of the neutralized solution before fluorescence measurements. A pH 
greater than 8 is necessary to ensure complete and rapid reaction of the CPM 
with CoA-SH. It is important to note that CPM is light sensitive, and fluorescence 
should be measured within one hour from the time of neutralization. It should 
also be pointed out that the difference in background CoA-SH evidenced in both 
figures 3 and 4, between each A and B panel can be explained by the fact that in 
the two cases where the ACP substrates are held at a higher concentration, 
there is higher background.  This is caused by the contaminating free thiol 
present in the ACP preparations. 
 This study introduces a method for safe and repeatable assays of fatty 
acid biosynthesis enzymes that utilize sulfhydryls. This method functions with 
exceptional repeatability and stability. Reliability will prove beneficial for 
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adaptation to high throughput screening and allow for rapid analysis of many 
enzymes, substrates and potentially inhibitors. Our approach utilizes 
commercially available reagents and functions without radioactive substrates or 
linking enzymes with linking substrates that can complicate analysis. Although 
sample handling in the assay is more involved than a continuous coupled assay, 
it is still straightforward and completed in a short amount of time.  
Thiol quantitation using CPM lends additional benefits to the approach 
described here. These methods will be directly applicable to studies of other fatty 
acid synthesis enzymes, including the KASI and KASII enzymes, as well as 
polyketide synthases that liberate thiols in the form of CoA-SH and generate 
ACP-bound intermediates within the reaction cycle [22,23]. Furthermore, the 
assay method is also applicable in screens of drug molecule libraries for novel 
antibiotics targeting FabD, FabH or other FAS enzymes [24]. 
 
Acknowledgement: 
This material is based upon work supported by the National Science Foundation 
under Award No. EEC-0813570, and by funds from the Roy J. Carver 
Department of Biochemistry, Biophysics & Molecular Biology at Iowa State 
University. Any opinions, findings, and conclusions or recommendations 
expressed in this material are those of the authors and do not necessarily reflect 
the views of the National Science Foundation. 
 
 
 
60 
 
Works Cited 
1. Nikolau BJ, Perera MA, Brachova L, Shanks B (2008) Platform biochemicals 
for a biorenewable chemical industry. Plant J 54: 536-545. 
2. Wakil SJ, Stoops JK, Joshi VC (1983) Fatty acid synthesis and its regulation. 
Annu Rev Biochem 52: 537-579. 
3. Maier T, Leibundgut M, Ban N (2008) The crystal structure of a mammalian 
fatty acid synthase. Science 321: 1315-1322. 
4. Leibundgut M, Maier T, Jenni S, Ban N (2008) The multienzyme architecture 
of eukaryotic fatty acid synthases. Curr Opin Struct Biol 18: 714-725. 
5. Leber C, Da Silva NA (2014) Engineering of Saccharomyces cerevisiae for the 
synthesis of short chain fatty acids. Biotechnol Bioeng 111: 347-358. 
6. Ratledge C (2004) Fatty acid biosynthesis in microorganisms being used for 
Single Cell Oil production. Biochimie 86: 807-815. 
7. Volker AR, Gogerty DS, Bartholomay C, Hennen-Bierwagen T, Zhu H, et al. 
(2014) Fermentative production of short-chain fatty acids in Escherichia 
coli. Microbiology 160: 1513-1522. 
8. Tsay JT, Oh W, Larson TJ, Jackowski S, Rock CO (1992) Isolation and 
characterization of the beta-ketoacyl-acyl carrier protein synthase III gene 
(fabH) from Escherichia coli K-12. J Biol Chem 267: 6807-6814. 
9. Davies C, Heath RJ, White SW, Rock CO (2000) The 1.8 A crystal structure 
and active-site architecture of beta-ketoacyl-acyl carrier protein synthase 
III (FabH) from escherichia coli. Structure 8: 185-195. 
10. Borgaro JG, Chang A, Machutta CA, Zhang X, Tonge PJ (2011) Substrate 
recognition by beta-ketoacyl-ACP synthases. Biochemistry 50: 10678-
10686. 
11. Marcella AM, Jing F, Barb AW (2015) Preparation of holo- and malonyl-[acyl-
carrier-protein] in a manner suitable for analog development. Protein Expr 
Purif 115: 39-45. 
12. Chung CC, Ohwaki K, Schneeweis JE, Stec E, Varnerin JP, et al. (2008) A 
fluorescence-based thiol quantification assay for ultra-high-throughput 
screening for inhibitors of coenzyme A production. Assay Drug Dev 
Technol 6: 361-374. 
13. Heath RJ, Rock CO (1996) Inhibition of beta-ketoacyl-acyl carrier protein 
synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J Biol 
Chem 271: 10996-11000. 
14. Dreier J, Li Q, Khosla C (2001) Malonyl-CoA:ACP transacylase from 
Streptomyces coelicolor has two alternative catalytically active 
nucleophiles. Biochemistry 40: 12407-12411. 
15. Misra A, Surolia N, Surolia A (2009) Catalysis and mechanism of malonyl 
transferase activity in type II fatty acid biosynthesis acyl carrier proteins. 
Mol Biosyst 5: 651-659. 
16. Ruch FE, Vagelos PR (1973) Characterization of a malonyl-enzyme 
intermediate and identification of the malonyl binding site in malonyl 
coenzyme A-acyl carrier protein transacylase of Escherichia coli. J Biol 
Chem 248: 8095-8106. 
61 
 
17. Molnos J, Gardiner R, Dale GE, Lange R (2003) A continuous coupled 
enzyme assay for bacterial malonyl-CoA:acyl carrier protein transacylase 
(FabD). Anal Biochem 319: 171-176. 
18. Sippel TO (1981) New fluorochromes for thiols: maleimide and 
iodoacetamide derivatives of a 3-phenylcoumarin fluorophore. J 
Histochem Cytochem 29: 314-316. 
19. Joshi VC, Wakil SJ (1971) Studies on the mechanism of fatty acid synthesis. 
XXVI. Purification and properties of malonyl-coenzyme A--acyl carrier 
protein transacylase of Escherichia coli. Arch Biochem Biophys 143: 493-
505. 
20. Szafranska AE, Hitchman TS, Cox RJ, Crosby J, Simpson TJ (2002) Kinetic 
and mechanistic analysis of the malonyl CoA:ACP transacylase from 
Streptomyces coelicolor indicates a single catalytically competent serine 
nucleophile at the active site. Biochemistry 41: 1421-1427. 
21. Kremer L, Nampoothiri KM, Lesjean S, Dover LG, Graham S, et al. (2001) 
Biochemical characterization of acyl carrier protein (AcpM) and malonyl-
CoA:AcpM transacylase (mtFabD), two major components of 
Mycobacterium tuberculosis fatty acid synthase II. J Biol Chem 276: 
27967-27974. 
22. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs 
over the 30 years from 1981 to 2010. J Nat Prod 75: 311-335. 
23. Fischbach MA, Walsh CT (2006) Assembly-line enzymology for polyketide 
and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. 
Chem Rev 106: 3468-3496. 
24. Campbell JW, Cronan JE, Jr. (2001) Bacterial fatty acid biosynthesis: targets 
for antibacterial drug discovery. Annu Rev Microbiol 55: 305-332. 
25. Qiu X, Choudhry AE, Janson CA, Grooms M, Daines RA, et al. (2005) Crystal 
structure and substrate specificity of the beta-ketoacyl-acyl carrier protein 
synthase III (FabH) from Staphylococcus aureus. Protein Sci 14: 2087-
2094. 
26. Khandekar SS, Gentry DR, Van Aller GS, Warren P, Xiang H, et al. (2001) 
Identification, substrate specificity, and inhibition of the Streptococcus 
pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH). J Biol 
Chem 276: 30024-30030. 
 
 
62 
 
 
CHAPTER 4: THE R117A VARIANT OF THE ESCHERICHIA COLI MALONYL-
COENZYME A:HOLO-(ACYL CARRIER PROTEIN) TRANSACYLASE FABD 
SYNTHESIZES NOVEL  
ACYL-(ACYL CARRIER PROTEINS) 
 
Aaron M. Marcella and Adam W. Barb 
Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology 
2437 Pammel Drive 
Molecular Biology Building, rm 4210 
Iowa State University, Ames, IA 50011 
 
A manuscript prepared for the Journal of Applied Microbiology and Biotechnology 
 
 
Highlights: 
-An R117A variant of the FabD enzyme efficiently generates malonyl-CoA 
-The variant can act on several non-cognate CoA substrates 
-FabD wild type and variant kinetic constants were determined with several acyl-
CoA substrates 
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Abstract 
The commercial impact of fermentation systems producing novel and 
biorenewable chemicals will flourish with the expansion of enzymes engineered 
to synthesize new molecules. Enzymes from prokaryotic fatty acid biosynthesis 
naturally generate highly reduced carbon-based molecules and are therefore 
promising engineering targets. Though a small degree of natural variability exists 
in fatty acid synthesis, the molecular space accessible through enzyme 
engineering is fundamentally limitless. Prokaryotic fatty acid biosynthesis 
enzymes also build carbon chains on a functionalized acyl carrier protein (ACP) 
that provides solubility, stability, a scaffold for interactions with the synthetic 
enzymes and represents an ideal platform to shuttle metabolites. This report 
describes the characterization of a transacylase enzyme that produces novel 
ACP-based primer and extender units for fatty acid biosynthesis. Unlike the 
malonyl-coenzyme A(CoA):holo-ACP transacylase (FabD) from Escherichia coli, 
the R117A variant synthesized acetyl-ACP, succinyl-ACP, isobutyryl-ACP, 2-
butenoyl-ACP, and β-hydroxybutyryl-ACP among others from holo-ACP and the 
corresponding acyl-CoAs. These reactions proceeded with specific activities from 
3.7-120 nmoles min-1 mg-1. FabD R117A maintained KM values for holo-ACP 
(~40 µM) and displayed small changes in KM for acetoacetyl-CoA (110±30 µM) 
and acetyl-CoA (200±70 µM) when compared to malonyl-CoA (80±30 µM). 
Reductions in FabD R117A kcat (malonyl-CoA = 8.4±0.1 s-1; acetyl-CoA = 0.05 
±0.01 s-1) accounted for the disparity in efficiency with different acyl-CoA 
substrates. Surprisingly, both FabD and FabD R117A utilized methylmalonyl-
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CoA, though with increased KMs of 580±100 µM and 330±90 µM, respectively. 
Thus, FabD R117A represents a novel catalyst that efficiently synthesizes a 
broad range of acyl-CoAs. The maintenance of acyl-CoA and holo-ACP binding 
affinities suggests FabD R117A is applicable to synthetic organisms that 
generate only moderate acyl-CoA and holo-ACP concentrations (10-100 µM). 
 
Introduction 
Chemicals produced from renewable sources have an opportunity to 
replace many petrochemicals in the near term and offer routes to novel materials 
and specialty chemicals [1]. Cellulosic ethanol production provides a model for 
the development of biorenewable resources that has proven profitable and 
efficient [2]. Contemporary development efforts focus on modifying existing 
biochemical pathways to produce valuable molecules from industrial microbe 
strains and are limited by the availability of expressible enzymes that harbor 
novel or unique activities [3,4].  
Prokaryotic fatty acid synthesis provides nearly ideal targets for 
engineering enzymes to synthesize novel products due to organizational 
simplicity and efficient chemistry [5]. Prokaryotic fatty acid biosynthesis 
generates relatively large volumes of highly reduced carbon based molecules 
and operates as a dissociated multi enzyme system unlike the single polypeptide 
mega-enzymes utilized by eukaryotes [4,6]. These prokaryotic biosynthetic 
enzymes, if changed to alter substrate specificity, offer many opportunities to 
65 
 
develop novel products that will be applicable in recombinant microbial industrial 
strains. 
 The malonyl-coenzyme A(CoA):holo-(acyl carrier protein(ACP)) 
transacylase (FabD) is one target for enzyme engineering that provides multiple 
options with respect to where in a fatty acid chain the modification may be 
directed. FabD transfers the malonyl moiety from malonyl-CoA to holo-ACP to 
form malonyl-ACP (Fig. 1A) [7].  
 
Figure 4-1.  The FabD reaction and active site organization. (A) FabD reaction 
showing first the formation of a malonyl-enzyme intermediate and the 
subsequent transacylation of holo-ACP to malonyl-ACP. (B) The panel of acyl-
CoA substrates tested here. Active site of the FabD wild type (C) and FabD 
R117A (D) enzymes. The active site pocket opened as a result of the R117A 
substitution is shown with a dashed white line in (D).  
 
Malonyl-ACP donates two carbons, following decarboxylation, as an extender 
unit for all subsequent fatty acid chain elongation reactions in Escherichia coli 
catalyzed by the ketoacyl synthases I (KASI), KASII, and KASIII [8]. An 
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engineered FabD that recognized a malonyl analog with branches at the central 
methylene moiety could act as a chain extender unit and introduce diversity 
along the fatty acid chain in a designed synthesis pathway. Alternatively, FabD 
engineered to transfer a variety of acyl substituents (lacking the terminal 
carboxylate moiety) could serve to prime fatty acid synthesis with a unique motif 
that will form the fatty acid ω terminus.  
E. coli FabD is also an excellent target for protein engineering due to its 
remarkable catalytic efficiency approaching the diffusion limit and the availability 
of high quality FabD structure models solved by x-ray crystallography [9,10]. We 
explored FabD amino acid variants to identify a form with broader substrate 
recognition than the wild-type enzyme. These efforts focused on expanding the 
substrate-binding pocket in the FabD active site, particularly with respect to 
recognition of the CoA acyl moiety. Figure 1C shows the FabD active site 
following a reaction with malonyl-CoA to generate a malonyl-FabD reaction 
intermediate [9]. The malonyl moiety forms an acyl linkage to the S92 sidechain 
and is stabilized at the distal carboxylate by the R117 guanidinium group [9]. 
Q11, Q63 and Q250 appear to stabilize the active site and H91 and H201 play 
important roles in catalysis [11].  
Active site substitutions generally reduce FabD activity, though these have 
not been thoroughly explored. Substitution at R117 eliminates an important 
carboxylate-guanidinium interaction with malonyl-CoA (Figure 4-1C) [12,13]. H91 
or H201 substitutions appear deleterious [11] and Q63 and Q11 likewise appear 
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essential [14]. Here we revisit the effect of these FabD amino acid substitution 
and thoroughly characterize the FabD R117A variant. 
 
Materials and Methods 
All materials were purchased from Sigma Aldrich unless otherwise noted. 
Protein preparation: Plasmids encoding FabD variants were prepared using the 
pET28b:FabD plasmid [10] and the Fusion PCR protocol [15]. FabD and FabD 
variants were purified as described previously [10]. FabD activity assays were 
completed as described [10]. Holo-ACP expression, purification and MALDI-MS 
was performed as described [16]. His-tagged and untagged holo-ACP were 
assayed independently as FabD substrates; specific activities showed similar 
results (4100 and 3200 μmoles/min/mg, respectively). Because the untagged 
ACP prep contained unidentified deacetylase activity and increased noise in the 
assays we used the His-tagged ACP for the assays. It should also be noted that 
both FabD and FabD R117A proved to be highly stable, remaining active for 2 
years stored at -80 °C in 25 % glycerol and maintained high levels of activity 
following multiple freeze thaw cycles. 
 
ESI-MS of intact ACP, FabD and FabD R117A: 
Protein (10 µL, 0.1 mg/mL in double distilled water) was applied to a C4 column 
and eluted from an Agilent 1260 liquid chromatography system with variable 
relative concentrations of Buffer A (0.1 % formic acid in water) and Buffer B (0.1 
% formic acid in acetonitrile) with a constant flow rate of 0.1 mL/min: 1 mL 95% A 
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plus 5% B, then 0.5 mL 100% B, and final 0.5 mL 95% A plus 5% B. ESI was 
conducted on a Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer 
(Thermo Scientific) with positive polarity at 35.0 eV, and a scan range of 700-
4000 m/z. 
 
ESI-MS of FabD R117A protease digests: 
Trypsin: FabD R117A was diluted to a final concentration of 0.2 mg/mL in a 25 
mM MOPS buffer with 100 μl final volume. This solution was boiled for 1 hour, 
the briefly centrifuged to collect all material at bottom of tube and then cooled on 
ice for 10 min. sequencing grade trypsin (Promega; 5 μg) was added and the 
reaction incubated for 18 h at 37 °C. The tryptic digest was applied to a C4 
column eluted from the LC system. The same two buffers used for the intact 
mass LC-MS mentioned above were used with the following gradient. First, 540 
μl of 95% A, 5% B was applied at 30 μl/min, followed by 150 μl of 65% A, 35% B 
at 30 μl/min. Then 300 μl 100% B at 60 μl/min was applied and 600 μl 95% A, 
5% B at 60 μl/min. Finally, 30 μl of 95% A, 5% B was applied at 30 μl/min. The 
ESI-MS spectrum was collected with positive polarity and the initial MS step had 
a scan range of 350-5000 m/z. The MS/MS step was done with a scan range of 
200-2000 m/z. 
 
Pepsin: FabD R117A was diluted from its stock to a final concentration of 0.2 
mg/mL in a 12.5 mM MOPS buffer with 100 μl final volume. This solution was 
boiled for 15 min and then cooled on ice for 10 min. Concentrated HCl (0.5 μl) 
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was added to the solution and an acidic pH was verified using litmus paper. 
Pepsin (Promega, 0.5 μg) in a 40 mM HCl solution was added and the reaction 
incubated for 18 hours. The reaction was stopped by boiling for 10 min. The 
pepsinized sample was subjected to the same LC-MS/MS as the trypsinized 
sample described above. 
 
Results 
Initial analyses –  The E. coli FabD active site is specifically designed to bind 
malonyl-CoA and provides no obvious unoccupied cavities to accommodate 
larger CoA-bound substituents (Figure 4-1C; [9]). R117 forms an ionic interaction 
with the malonate carboxylate in the active site, and will open a large new cavity 
in the the FabD substrate-binding pocket if substituted with Ala (Figure 4-1D). We 
prepared FabD and FabDR117A to test the substrate binding potential following 
R117A substitution. Expression and purification of FabD and FabD R117A 
resulted in near homogeneous preparations at 35 mg/L and 17 mg/L, 
respectively, following anion exchange and gel filtration chromatography as 
judged by SDS-PAGE analysis (Figure 4-2). FabD, FabD R117A and the holo-
ACP substrate were analyzed using ESI-MS to verify molecular mass and purity 
(Figure S1). FabD and holo-ACP displayed masses within 3 Da of the expected 
values, but the deconvoluted mass of FabD R117A was 29 ±3 Da less than 
expected. ESI-MS/MS of tryptic and peptic FabD R117A digests identified 
peptides corresponding to 95.5% of the protein sequence and matched expected 
masses to within 0.01 Da (Figure S2). This result indicates the 29 Da deviation, 
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which was found on all detectable FabD R117A protein, was limited to the 4.5% 
of the protein sequence not identified in the ESI-MS/MS analysis. It is important 
to note that the 95.5% coverage includes all of the active site residues and a 
mass shift of 29 ±3 Da could be explained by an unidentified N-terminal 
modification alone or in combination with Q deamidation (-14 Da). ESI-MS/MS 
analysis identified all but one Q residue. 
 
Figure 4-2. Purification of FabD and FabD R117A. (A) The FabD elution profile 
from a Superdex 200 size exclusion column shows a single symmetric peak. (B) 
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SDS-PAGE analysis of fractions from (A). (C) SDS-PAGE gel of FabD R117A 
purification using the S200 column.  
 
Specific activities of FabD and FabD R117A - FabD and FabD R117A activity 
was quantified using a non-continuous fluorescence based assay with 250 µM 
acyl-CoA and 75 µM holo-ACP [10]. The assay strategy uses a thiol reactive 
fluorescent probe to measure CoA-SH production [17] and is applicable to FabD 
assays with any stable acyl-CoA. This assay technique includes a step to 
precipitate holo-ACP (a free thiol with a concentration in this assay equal to the 
starting holo-ACP concentration minus the concentration of CoA-SH) from the 
CoA-SH containing reaction using trichloroacetic acid before neutralizing and 
adding the thiol-reactive reagent. Both FabD and FabD R117A showed linear 
accumulations of CoA-SH over time in the presence of holo-ACP and malonyl-
CoA during the time limit of the assay (Figure S3). Measurement of these initial 
velocities proved highly repeatable. The specific activity of FabD (4100 µmoles 
min-1 mg-1) was comparable with a published value of 1800 µmoles min-1 mg-1 
[18] and R117A displayed a lower, though still considerable, activity (13 µmoles 
min-1 mg-1) with holo-ACP and malonyl-CoA substrates (Table 4-1). The activity 
of FabD and FabD R117A towards a panel of acyl-CoAs showed significant 
differences between the two enzymes. This panel contained acyl groups with 
many features of interest including odd chain length, branching, and ω or ω-1 
functionalization (Figure 4-1B). These substrates potentially provide a 
biorenewable path to branched or alternatively functionalized compounds. The 
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fluorescence assay provided the specific activity towards each substrate, with the 
exception of succinyl-CoA. 
Table 4-1. Specific activity of FabD and FabD R117A with various CoA 
substrates (200 µM) and 75 µM holo-ACP. 
 
 
 
 
 
CoA Substrate 
 
FabD 
Spec. 
Activity 
(μmoles/
min/mg) 
FabD 
R117A  
Spec. 
Activity 
(μmoles/
min/mg) 
malonyl-CoA 4100 13 
acetoacetyl-CoA 0.0016 0.060 
methylmalonyl-CoA 270 3.2 
acetyl-CoA n.a. 0.12 
propionyl-CoA n.a. 0.052 
succinyl-CoA n.a. 0.016 
butyryl-CoA n.a. 0.011 
2-butenoyl-CoA n.a. 0.0054 
β-hydroxybutyryl-CoA n.a. 0.0050 
isobutyryl-CoA n.a. 0.0037 
isovaleryl-CoA n.a. 0.0010 
n.a.: no activity detected 
 
  
 
Succinyl-CoA is labile at the neutral pH used for the assays [19]. As a 
result, MALDI-TOF MS spectra of aliquots removed early in the reaction provided 
data points for the specific activity measurement. 
It was surprising that both FabD and FabD R117A utilized methylmalonyl-
CoA, a substrate not commonly found in E. coli (Table 4-1). FabD R117A 
converted acetoacetyl-CoA with a specific activity that was four times greater 
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than FabD. Only FabD R117A could utilize acetyl-, propionyl-, butyryl-, isobutyryl-
, succinyl-, isovaleryl-, β-hydroxybutyryl, and 2-butenoyl-CoA (Table 4-1). 
Conversion of holo-ACP to acyl-ACP using these acyl-CoAs was verified using 
MALDI-MS to eliminate the possibility of CoA-SH generation resulting from acyl-
CoA hydrolysis catalyzed by FabD R117A during the assay (Figure 4-3 and 
Table S1).  
 
 
Figure 4-3. Representative MALDI-TOF MS analysis of doubly-charged holo-
ACP and acyl-ACPs. S1 refers to holo-ACP; S2 is holo-ACP with a gluconylation 
at the N-terminal His6 tag [16]; P1 and P2 refer to the unmodified and 
gluconylated products, respectively, indicated in the title of each panel. P3 and 
P4 are the result of decarboxylation of P1 and P2 for malonyl-ACP and 
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methylmalonyl-ACP. Expected and observed masses for each peak are shown in 
Table S1. 
 
MALDI-MS allows for screening many acyl-ACP products quickly with minimal 
sample requirement while providing the resolution necessary to separate peaks 
corresponding to the reaction product and substrate. It is surprising FabD R117A 
showed significant activity towards acetyl-CoA, an inhibitor of E. coli FabD [20]. 
FabD R117A utilized acyl-CoAs with shorter apolar acyl moieties more readily 
than longer and branched apolar acyl moieties (acetyl > propionyl > butyryl > 
isobutyryl > isovaleryl). FabD R117A tolerated polar acyl moieties surprisingly 
well with significant activity towards acetoacetyl-CoA and succinyl-CoA.  
KM and kcat comparisons - Specific activity measurements provide a convenient 
metric to compare a wide range of substrates, but do not offer detailed 
information regarding relative substrate affinity that could be informative when 
designing new catalysts based on the FabD R117A scaffold. The FabD and 
FabD R117A enzymes were assayed with malonyl-CoA and holo-ACP. Initial 
velocities, determined from the linear portion of reaction progress curves, 
approached an asymptote at high substrate concentrations (Fig 4-4).  
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Fig 4-4.  Plots of FabD and R117A saturation kinetics. Initial velocity v. substrate 
plots for FabD with varied malonyl-CoA (A; 125 µM holo-ACP) and varied holo-
ACP (B; 250 µM malonyl-CoA) and plots of FabD activity with methylmalonyl-
CoA (C; 125 µM holo-ACP) and holo-ACP (D; 250 µM methylmalonyl-CoA). The 
FabD R117A variant shows similar profiles with malonyl-CoA (E; 125 µM holo-
ACP) and holo-ACP (F; 250 µM malonyl-CoA) and plots of FabD R117A activity 
with methylmalonyl-CoA (G; 125 µM holo-ACP) and holo-ACP (H; 250 µM 
methylmalonyl-CoA).  
 
Fitting these data with the Michalis-Menten equation revealed KM and kcat values 
(Table 4-2; Fig. 4).  
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Table 4-2. Kinetic parameters for FabD and FabD R117A are reported ± one 
standard deviation of the mean. 
FabD 
Spec. Activity 
μmoles/min/mg 
Acyl-CoA 
KM1 (μM) 
Holo-ACP 
KM2 (μM) kcat1 s-1 kcat2 s-1 
Malonyl-CoA [10] 4100 60 ± 20 40 ± 10 2100 ± 200 2600 ± 200 
Methylmalonyl-CoA 270 580 ± 100 20 ± 7 1000 ± 100 400 ± 40* 
Acetoacetyl-CoA 0.0016 n.d. n.d. n.d. n.d. 
Acetyl-CoA n.a. n.d. n.d. n.d. n.d. 
           
FabD R117A 
Malonyl-CoA 13 80 ± 30 30 ± 10 8.5 ± 0.8 11 ± 2 
Methylmalonyl-CoA 3.2 330 ± 90 11 ± 3 5.0 ± 0.7 2.6 ± 0.1* 
Acetoacetyl-CoA 0.060 110 ± 30 30 ± 20 0.041 ± 0.005 0.038 ± 0.010 
Acetyl-CoA 0.12 200 ± 70 40 ± 10 0.029 ± 0.005 0.052 ± 0.006 
 
n.d.: not determined 
n.a.: no activity detected 
*- measured with sub-saturating amounts of methylmalonyl-CoA (250 µM) 
 
Next, the most active substrates for FabD and FabD R117A were selected for 
measurement of relative substrate affinity (estimated with KM) and catalytic rates 
(kcat). With respect to malonyl-CoA, the R117A substitution primarily affected kcat 
(277-fold reduction) with no measurable effect on KM for either malonyl-CoA or 
holo-ACP (Table 4-2 and Fig 4-4). The methylmalonyl-CoA KM was higher for 
both FabD (10-fold) and FabD R117A (4-fold) with smaller effects on kcat (2.6-fold 
and <2-fold, respectively).  
FabD R117A recognized acetoacetyl-CoA and acetyl-CoA with a 
moderate increase in CoA KM (1.4- and 2.5-fold, respectively), no measureable 
effect on holo-ACP KM, but much greater reductions in kcat (200-300 fold). It is 
easy to understand how altering the substrate composition can alter binding 
affinity as estimated by KM, but it is important to note that KM is not a strict 
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measure of substrate affinity and substrate binding energy can contribute to 
catalytic rate [21]. FabD utilized acetoacetyl-CoA poorly and didn’t recognize 
acetyl-CoA, as a result of the low activity it was not feasible to measure KM and 
kcat values and compare with FabD R117A. 
FabD-catalyzed decarboxylation of malonyl-ACP – A reaction containing E. coli 
FabD, malonyl-CoA and holo-ACP generated a roughly 50:50 mixture of acetyl-
ACP and malonyl-ACP (Fig 4-5), likely from malonyl decarboxylation during the 
catalytic cycle.  
 
Fig 4-5. Malonyl decarboxylation during FabD catalysis. FabD and FabD R117A-
catalyzed malonyl transfer leads to decarboxylation at early reaction timepoints 
using malonyl-CoA as the donor substrate. Only FabD R117A, however, appears 
to slowly recycle acetyl-ACP in a CoA-SH dependent manner, liberating holo-
ACP for another malonyltransferase reaction. S1 refers to holo-ACP; S2 is holo-
ACP gluconylated at the N-terminal His6 tag; P1 and P2 are malonyl-ACP and 
gluconylated malonyl-ACP, respectively. P3 and P4 are the result of 
decarboxylation of P1 and P2.  
 
This unanticipated reaction previously stood as an impediment to preparing 
malonyl-ACP in vitro with high levels of purity for FabH, FabB and FabF assays 
until we determined that following long incubations a contaminant in the ACP 
preparation efficiently removed the acetyl moiety from ACP in the presence of 
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CoA-SH [16]. Indeed, if high levels of acetyl-ACP are formed from malonyl 
decarboxylation during FabD catalysis, E. coli must have mechanism to 
catabolize acetyl-ACP. Two independent groups identified an acetyl-CoA:holo-
ACP transferase activity and performed a basic characterization of the enzyme, 
but it was never cloned [22,23]. This contaminating acetyltransferase activity 
allowed our laboratory to prepare malonyl-ACP to high purity and could be 
removed from holo-ACP preparations using a Superdex75 column (data not 
shown). 
Preparations of malonyl-ACP formed using FabD R117A, following a 
longer incubation period, show dramatically lower levels of contaminating acetyl-
ACP compared to malonyl-ACP (Fig 5). We previously showed FabD R117A 
utilizes acetyl-CoA to produce acetyl-ACP (Table 4-2 and Figure 4-3), and FabD 
R117A must also recycle acetyl-ACP formed in a reaction containing malonyl-
CoA and holo-ACP. These reactions utilized holo-ACP purified from a 
Superdex75 column that removed contaminating native acetyltransferase activity. 
The FabD R117A-catalyzed acetyltransferase activity occurs slower than the 
malonyltransferase activity and also must occur when CoA-SH becomes 
available as an acetyl acceptor following the malonyl transfer reaction.  
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Our laboratory now uses FabD R117A when preparing malonyl-ACP because of 
the acetyltransferase activity and because FabD R117A preparations still contain 
a high degree of malonyltransferase activity. 
 
Discussion 
 FabD R117A transferred a wide variety of acyl substituents from CoA to 
holo-ACP. Introducing a large range of new activities into an enzyme and 
organism that did not previously produce these products shows the clear effect of 
the R117A substitution, and eliminates the possibility of residual FabD activity 
contributing to the observed signal [24]. Removing the R117 sidechain enhanced 
the breadth of FabD substrate recognition, likely by opening a new pocket in the 
enzyme active site that accepts hydrophobic and polar CoA acyl groups (Figure 
4-1D).  
The acyl moieties tested here contain added chemical functionality and 
will lead to novel downstream products, some of which are shown in Figure 4-6. 
The resulting acyl-ACPs represent novel potential extender and primer 
substrates for fatty acid biosynthesis that have the potential to introduce a high 
degree of functionalization, resulting in branched chains, odd-numbered chains 
and fatty acid-like molecules with a negative charge, an alkene, hydroxyl or 
carboxyl groups (Figure 4-1C and 6). The use of an ACP scaffold to achieve 
designed chemical synthesis in vivo potentially provides access to additional fatty 
acid biosynthesis enzymes, though further optimization of these enzyme targets 
may be required. 
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Figure 4-6. Potential strategies for developing new molecules using the novel 
ACPs generated by FabD R117A. FabD R117A generates unique ACP 
molecules with “primer units” in columns A-C or a unique “extender unit” in 
column D that potentially can be condensed, reduced, elongated and hydrolyzed 
to produce novel biorenewable chemicals including plastics and lipids. 
 
Although the E.coli FabH enzyme is not reported to act on branched chain CoA 
substrates, Streptomyces glaucescens FabH will, lending support to the idea of 
feeding modified substrates to downstream enzymes [25]. It may be necessary to 
pursue further engineering of other enzymes in the pathway to accept the novel 
acyl-ACPs reported here.  
One exciting FabD R117A catalytic product is succinyl-ACP (Figure 4-3). 
The CoA substrate for this reaction, succinyl-CoA is an abundant intermediate in 
the E. coli citric acid cycle (~200 µM in vivo) [26]. Following succinate transfer to 
holo-ACP, succinyl-ACP is available for conversion to adipyl-ACP following 
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condensation with malonyl-ACP and one round of FabG-FabA-FabI catalyzed 
reductions to remove the 3-ketone (Figure 4-6) [5]. Adipyl-ACP hydrolysis leads 
to adipic acid, an important diacid target of biorenewable chemical production 
that represents a drop-in biorenewable replacement for nylon 6,6 polymerization 
[27]. 
Branched chain fatty acids can be formed either by using a modified ACP 
extender or primer substrate. Isobutyryl-ACP acting as the primer substrate 
would produce an ω-branched fatty acid. Using methylmalonyl-ACP as an 
extender unit will result in methyl branches at every two carbons along the 
growing fatty acid chain yielding a highly substituted fatty acid. The donor 
substrate methylmalonyl-CoA is formed from succinyl-CoA by methylmalonyl-
CoA mutase, an E. coli enzyme [28]. Branched chain and substituted fatty acids 
may be beneficial to the materials industry, providing biorenewable sources for 
novel lubricants, oils and other materials.  
The FabD R117A substitution introduced substrate recognition plasticity 
into the FabD scaffold. A cursory examination of Table 4-1 might suggest the 
modest activity levels of FabD R117A will limit the potential application when 
compared to FabD, an enzyme with very high specific activity. However, FabD 
R117A displays significant specific activity comparable to the ‘average’ enzyme 
[29]. The shape of the FabD R117A substrate-binding pocket is likely not 
perfectly complimentary to each acyl substituent, unlike FabD and malonyl-CoA, 
and as a result FabD R117A activity is likely preserved by the contribution of 
binding energy from the CoA nucleotide-protein interaction which appeared 
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unaffected by R117 substitution. Though it is unknown where ACP binds, ACP-
FabD interactions were also preserved given the similarity of holo-ACP KMs 
(Table 4-2). Further proof of FabD R117A activity comes from near-complete 
conversion of holo-ACP to acyl-ACP using each of these acyl-CoAs and mild 
reaction conditions (Fig 4-3). As a result of this minor impairment, it is possible 
an engineered microbe would need to express a higher level of FabD R117A 
when compared to intrinsic FabD to achieve suitable product concentrations. 
Increased expression is appropriate because the KM values are only minimally 
perturbed, and represent reasonable goal concentrations for introducing non-
cognate acyl-CoA biosynthesis [30,31].  
 Promiscuous enzyme paralogs with broad substrate recognition profiles 
represent branch points in enzyme evolution ([32] among others) and FabD 
R117A is expected to represent a similar branch point as a designed enzyme. It 
should be possible to engineer specific enzyme forms based on FabD R117A 
that will react with higher rates, greater affinities, and higher specificity towards 
each acyl-CoA. Such future designs would overcome rate-related limitations to 
industrial implementation with respect to the FabD R117A parent design. Broad 
specificity may not be negative characteristic, if the engineered microbe 
synthesizes a limited range of potential acyl-CoA substrates. Biosynthetic routes 
to many of the acyl-CoAs investigated here are described (many come from the 
citric acid cycle and amino acid biosynthesis/degradation) and would serve as a 
starting point to strain engineering. 
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Supplemental Information for Chapter 4 
 
Supplemental Table 4-1. This table is related to Figure 4-3. Comparison of 
expected doubly-charged ACP masses (Da) and masses observed by MALDI-
TOF MS. S1 refers to holo-ACP; S2 is holo-ACP with a gluconylation at the N-
terminal His6 tag; P1 and P2 are the respective products. P3 and P4 are the 
result of decarboxylation of P1 and P2 for malonyl-ACP and mathylmalonyl-ACP. 
 
 
 
 
 
 
 
 
 
 S1  S1  
 S2  S2   P1 P1  P2 P2  
obs exp ∆ obs exp ∆ obs exp ∆ obs exp ∆ 
Holo-ACP 5237.2 5231.6 5.6 5327.6 5320.2 7.4 - - - - - - 
Malonyl-ACP 5235.4 5231.6 3.8 5324.2 5320.2 4.0 5279.4 5274.6 3.8 5368.5 5363.2 3.8 
Methylmalonyl-ACP 5232.2 5231.6 0.6 5321.4 5320.2 1.2 5281.2 5281.6 0.6 5371.2 5368.7 0.6 
Acetoacetyl-ACP 5235.9 5231.6 4.3 5325.6 5320.2 5.4 5277.4 5273.6 4.3 5367.7 5362.2 4.3 
Acetyl-ACP 5230.7 5231.6 0.9 5320.0 5320.2 0.2 5251.4 5252.6 0.9 5340.6 5341.2 0.9 
Propionyl-ACP 5227.6 5231.6 4.0 5317.6 5320.2 2.6 5258.3 5259.6 4.0 5347.2 5348.2 4.0 
Succinyl-ACP 5236.0 5231.6 4.4 5325.8 5320.2 5.6 5287.3 5281.6 4.4 5375.7 5370.2 4.4 
Butyryl-ACP 5231.9 5231.6 0.3 5321.5 5320.2 1.3 5267.3 5266.6 0.3 5356.9 5355.2 0.3 
Isobutyryl-ACP 5228.6 5231.6 3.0 5318.3 5320.2 1.9 5264.3 5267.1 3.0 5353.7 5355.7 3.0 
Hydroxybutyryl-ACP - 5231.6 - 5322.2 5320.2 2.0 5277.4 5274.6 2.8 5365.7 5363.2 2.5 
Butenoyl-ACP 5233.0 5231.6 1.4 5322.4 5320.2 2.2 5267.1 5265.6 1.4 5357.3 5354.2 1.4 
Isovaleryl-ACP 5231.4 5231.6 0.2 5320.2 5320.2 0.0 5273.6 5273.6 0.2 5362.9 5362.2 0.2 
             
  
P3  P3  
 
P4  P4  
       
obs exp ∆ obs exp ∆       
Malonyl-ACP 5255.4 5252.6 2.8 5346.8 5341.2 5.6       
Methylmalonyl-
ACP 5260.6 5259.6 1.0 - 5348.2 -       
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Figure S4-1. This figure is related to Figure 4-2. ESI-MS of holo-ACP, FabD and 
FabD R117A. Raw MS spectra of the manifold of charged states for holo-ACP 
(A), FabD (C), and FabD R117A (E). Devoncoluted MS of holo-ACP (B), FabD 
(D), and FabD R117A (F). Holo-ACP (B) has two major forms that were 
previously characterized, one without an N-terminal methionine and one with 
gluconoylation of the N-terminal 6x histidine tag [33]. 
 
 
85 
 
 
Figure S4-2. This figure is related to Figure 4-2. Peptide coverage of FabD 
R117A from tryptic (blue lines) and peptic (red lines) digests analyzed by ESI-
MS/MS. This analysis revealed positive identification of peptides corresponding 
to 95.5% of the protein. The R117A site is shown as a bold green “A” in the third 
line of text. 
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Figure S4-3. This figure is related to Fig 4-4 and Table 4-1. Reaction progress 
curves for representative enzyme-catalyzed assays. Initial velocity 
measurements were collected using FabD (A) and FabD R117A (B). 
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Highlights: 
Structure of the Eschericia Coli holo-ACP synthase enzyme determined 
Structure of the E. Coli holo-ACP synthase in complex with holo-ACP was 
determined  
Binding energies determined for the formation of a product complex 
NMR was used to validate the X-ray crystallography structures 
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Abstract: 
The Escherichia coli holo-(acyl carrier protein) synthase (ACPS) catalyzes the 
coenzyme A-dependent activation of apo-ACPP to generate holo-(acyl carrier 
protein) (holo-ACPP) in an early step of fatty acid biosynthesis. ACPS is 
sufficiently different from the human fatty acid synthase to justify the 
development of novel ACPS-targeting antibiotics. Here we present two models of 
E. coli ACPS in apo- and product-bound forms solved by X-ray crystallography to 
1.85 Å and 3.85 Å, respectively. Trimeric ACPS binds three holo-ACPP 
molecules to form a 3:3 hexamer with strong affinity and negative cooperativity. 
The first equivalent of holo-ACPP bound with a KD = 50 nM, followed by the 
binding of two more equivalents of holo-ACPP with KD = 1 µM. Solution NMR 
spectroscopy experiments validated the ACPS binding interface on holo-ACPP 
using chemical shift perturbations and the relative orientation of holo-ACPP to 
ACPS by fitting residual dipolar couplings. The structure, strong affinity and 
negative cooperativity of ACPS for holo-ACPP suggests a previously 
undescribed role of ACPS residues 65-94 in the regulation of fatty acid 
biosynthesis.  
Introduction: 
Fatty acid biosynthesis is essential for all organisms to form membranes, 
signaling and energy storage molecules [1] [2,3,4]. Cell membranes are 
comprised of fatty acids packaged into various glycerophospholipids that contain 
two fatty acyl tails and one polar head group. The membrane creates a semi-
permeable barrier that helps cells maintain a balance of pH, charge, water, and 
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small molecules to survive [5,6]. The separation is not only important to protect 
from degradation and maintaining the interior components of the cell, but also for 
energy generation. Membranes provide the necessary separation of two 
compartments (cytosol and intermembrane space) in prokaryotes which in turn 
allows the proton motive force to generate ATP molecules by ATP synthase [7,8]. 
In eukaryotes, membranes also function as dividers for the various organelles 
and providing diffusion barriers within the cytoplasm [9]. 
Prokaryotic fatty acid biosynthesis is distinct and offers targets for 
antibiotic development [10,11,12]. Eukaryotes use a single polypeptide encoding 
all fatty acid biosynthesis activities unlike the multi enzyme system employed by 
prokaryotes and plants [11,12,13]. Thus, understanding the structure and 
function of the enzymes involved will greatly aid further studies into the 
mechanisms of fatty acid biosynthesis and potential inhibition. 
Fatty acid biosynthesis in Escherichia coli is initiated by the transfer of the 
phosphopantetheine moiety from coenzyme A (CoA) to the Serine 36 hydroxyl on 
the acyl-carrier-protein (ACPP) generating holo-ACPP catalyzed by the holo-
ACPP synthase (ACPS) (Figure 5-1) [14,15,16].  
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Figure 5-1. Holo-ACP synthase (ACPS) transfers the phosphopantetheine 
moiety from coenzyme A to Ser36 of apo-(acyl carrier protein; ACPP) to form 
holo-ACPP in an initial reaction of fatty acid biosynthesis. 
There are several crystal structures of the enzyme from various gram positive 
bacteria, but only one from a gram negative bacterium [17]. ACPS forms a trimer 
with an aspartate and glutamate coordinating the catalytic magnesium ion in the 
active site. The magnesium ion activates a nearby water to perform a hydrolysis 
reaction on the phosphodiester bond of CoA leaving behind the 
phosphopantetheine moiety [14]. The final step is transferring 
phosphopantetheine to ACPP-Ser36, forming a phosphodiester bond. This 
reaction serve to activate holo-ACPP to serve as a scaffold for the growing fatty 
acid chain in the fatty acid biosynthesis pathway. A structure of ACPS in complex 
with holo-ACPP from Bacillus subtilis shows a 3:3 binding stoichiometry [14]. 
However, it is less clear how gram negative ACPS proteins are organized and 
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holo-ACPP binding is achieved. Multiple reports indicate the primary E. coli 
ACPS oligomer in solution was a homodimer [18,19,20]. 
 Previous enzymatic studies on the ACPS enzyme showed what was 
interpreted as substrate inhibition by ACPP [18,20]. Initial kinetic characterization 
of the E. coli enzyme revealed what appeared to be substrate inhibition by ACPP 
above concentrations of 2 μM and set an upper bound on the KM of 1 μM [20]. 
Later work confirmed this observation and reported a similar KM for ACPP of 1.3 
μM and displaying clear inhibition at higher concentrations of ACPP [18]. This 
substrate inhibition is interesting as it supports our observation of product 
inhibition by holo-ACPP with a KD similar to the reported KMs of 1 μM. 
We previously observed a homogenous complex formed by holo-ACPP 
and ACPS eluted at ~100 kDa from a gel filtration column, a mass much greater 
than the mass of either protein (9 and 14 kDa, respectively [21]. To determine the 
oligomeric stoichiometry, structural organization and functional characteristic of 
holo-ACPP binding by ACPS, we determine the investigated apo ACPS and 
ACPS in complex with holo-ACPP using a combination of X-ray crystallography, 
solution NMR spectroscopy and isothermal titration calorimetry. 
Materials and Methods: 
All materials were purchased from Sigma Aldrich unless otherwise noted. 
Expression and Purification of ACPS: N-terminal 6xHis-tagged ACPP and 
untagged ACPS were expressed described previously [21]. The 6xHis-holo-
ACPP:ACPS complex was purified on a 5 mL Ni-NTA column (Qiagen) that was 
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equilibrated with 3 column volumes (cv) buffer A (25 mM Tris-HCl, 500 mM 
sodium chloride, pH 8.5), then the 6xHis-holo-ACPP:ACPS complex was eluted 
with a linear gradient of 0-50% buffer B (Buffer A supplemented with 1 M 
imidazole) over 5 cv followed by a final 100 % buffer B elution for 1 cv and re-
equilibrated with 3 cv of buffer A. Fractions containing 6xHis-holo-ACPP and 
ACPS were diluted >4-fold with 25 mM Tris-HCl, pH 8.5 and loaded onto a 120 
mL Q-Sepharose column (GE Life Sciences). The Q column was washed with 
0.5 cv of buffer C (25 mM MOPS, 1 mM EDTA, 2 mM β-mercaptoethanol, pH 
7.1) following protein loading followed by a linear gradient from 20-60% buffer D 
(C plus 1 M potassium chloride) over 2 cv, then a 0.2 cv wash with 100% buffer 
D and then re-equilibrated with 1.2 cv buffer C. Fractions containing ACPS were 
concentrated using a 3 kDa cutoff Amicon ultra centrifugation filter unit (EMD 
Millipore) and loaded onto a Superdex 75 column (GE Life Sciences) equilibrated 
and eluted with 25 mM MOPS, 100 mM sodium chloride, 1 mM dithiothreitol, 10 
mM magnesium chloride pH 7.1. Fractions containing ACPS were concentrated 
using a 3kDa cutoff filter unit and stored at 4 °C for less than 72 h. 
Expression and Purification of holo-ACPP: The open reading frame encoding 
ACPP was cloned in a manner that excluded the translation of an N-term 6xHis 
tag, but added a single glycine as the second residue, into a pET DUET vector 
that already contained ACPS. Holo-ACPP was expressed as described above, 
and purified using the Q-sepharose and Superdex 75 chromatography steps 
described above. Purified holo-ACPP was diluted to 25% glycerol and stored at a 
concentration of ~2 mM at -80°C. Prior to NMR, X-ray crystallography or ITC 
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experiments, holo-ACPP was desalted into a buffer containing 25 mM MOPS, 
100 mM sodium chloride, 10 mM magnesium chloride, 1 mM dithiothreitol pH 7.1 
using a 5 mL G25 resin column. MALDI-TOF-MS analysis of holo-ACPP was 
described [21]. 
Crystallization of holo-ACP Synthase: Purified holo-ACPP and ACPS were 
mixed at a 1.1:1 molar ratio, loaded onto a Superdex 200 column (GE Life 
Sciences) and complex eluted with a buffer containing 25 mM MOPS, 100 mM 
sodium chloride, 1 mM dithiothreitol, 10 mM magnesium chloride, pH 7.1. 
Complex was concentrated to 8.5 mg/mL with a 3 kDa cutoff filter unit and 
diffraction quality plate crystals containing only holo-ACP synthase were obtained 
in 100 mM HEPES, pH 7.5 and 1.8-2.2 M sodium formate or 100 mM HEPES, 
pH 7.5 and 1.8-2.2 M sodium nitrate using the hanging drop method. Crystals 
were cryoprotected using 10% ethylene glycol diluted in mother liquor and 
crystals were flash frozen in liquid nitrogen. Data was collected on the 23-ID-B 
beamline at Argonne National Laboratory’s Advanced Photon Source (APS) with 
a MAR300 detector. Data was indexed, merged, and scaled using HKL-2000 
[22]. Molecular replacement was completed using PHENIX Phaser-MR with a 
Bacillus subtilis ACPS search model (PDB-1F7T). After initial molecular 
replacement and limited refinement using Phenix.Refine [23], refinement was 
finalized using Refmac5 [24,25]. Statistics for data collection and refinement are 
shown in Table 5-2. Structure figures were prepared using PyMol (Schrödinger, 
Inc). Structure coordinates and electron density files were deposited in the PDB 
as 5VBX. 
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Crystallization of holo-ACPP:ACPS complex: Purified holo-ACPP and ACPS 
were mixed at a 1.1:1 molar ratio and then loaded onto a Superdex 200 column. 
Complex was eluted with a buffer containing 25 mM MOPS, 100 mM sodium 
chloride, 1 mM dithiothreitol, 10 mM magnesium chloride pH 7.1 (Fig S5-1) and 
concentrated to 9 mg/mL using a 3 kDa cutoff filter unit. Diffraction quality rod 
crystals were obtained in 16-48 hours in the following conditions: 100 mM Bis-
Tris propane, pH 7.0, (18-22% PEG 6k or 18-22% PEG 10k) and 100 mM 
sodium cacodylate, pH 6.5, (18-22% PEG 6k or 18-22% PEG 10k) using the 
hanging drop method mixing 1 μl protein with 1 μl mother liquor. Crystals were 
cryoprotected in either 10% 2,3, butanediol diluted in mother liquor or 100% 
Paratone-N and flash frozen with liquid nitrogen. Data was collected on the 23-
ID-D beamline at APS with a Pilatus3 6M detector. Data was indexed, merged 
and scaled using HKL-2000. Three datasets were collected from two different rod 
crystals (two datasets from one crystal and one dataset from a separate crystal). 
The two datasets from the first crystal were collected with 2 second exposure 
times and 1 degree/frame (60 and 45 frames for each dataset). The final dataset 
was collected using a 0.5 second exposure time and 0.5 degrees/frame (162 
frames). Following indexing and integration of each individual dataset in HKL-
2000, data was scaled without merging the originally indexed reflections. These 
datasets were then merged and scaled together using the Aimless program in 
CCP4i. Iterative molecular replacement was performed using PHENIX Phaser-
MR and the E. coli ACPS protein model determined in this manuscript. ACP 
molecules (1ACP) [26] were fit into the density using molecular replacement after 
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four ACPS trimers were placed in the asymmetric unit. After five ACP molecules 
were identified, the remaining unplaced ACPP monomers and ACPS trimer were 
fit using the previously identified sites as a guide. Final refinement was 
performed using Refmac5. Structure coordinates and electron density files were 
deposited in the PDB as 5VCB. 
Labeled ACP preparation: [15N]-holo-ACPP was expressed and purified as 
described above using M9 medium supplemented with [15N]-ammonium chloride. 
[15N,2H]-holo-ACPP was prepared by growing an overnight 5 mL culture of the 
untagged ACPP construct in Luria-Bertani medium; this culture was added to 1 
liter of 15N labeled M9 medium in H2O and grown to an OD600 of 0.44. At this 
point, the cells were pelleted with centrifugation in autoclaved bottles and 
resuspended in 1 L M9 medium supplemented with [15N]-ammonium chloride and 
prepared with 99.5% 2H2O. This culture was grown to OD600 = 0.8, then protein 
expression was induced with 0.5 mM IPTG and the culture was incubated with 
orbital shaking for 18 h at 18 °C. Holo-ACPP was purified as previously 
described. MALDI-TOF-MS spectra following purification showed ~85% [2H, 15N] 
labeling (data not shown). For backbone assignments of holo-ACPP, a 0.5 L 
culture of [15N,13C]- M9 medium was used for expression containing 0.5 g [15N]-
ammonium chloride and 1 g [13CU]-glucose (Cambridge Isotopes). 
Backbone Resonance Assignment: All NMR experiments were performed on a 
16.4T instrument equipped with a Bruker Avance II console and a 5 mm 
cryoprobe at 30 °C. The NMR sample for the assignments contained 300 µL of 
1.2 mM [13C,15N]-holo-ACPP, 25 mM MOPS, 100 mM sodium chloride, 1 mM 
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dithiothreitol, 10 mM magnesium chloride, 1 mM DSS, and 5% 2H2O, pH 7.1. 
CBCANH and CBCACONH experiments were collected with 16 scans/FID, 50 
total points in the 15N dimension and 100 total 13C points. The HNCO experiment 
was collected with 4 scans/FID, 50 total points in the 15N dimension and 100 total 
points for 13C. Data were processed using TopSpin, NMRPipe [27] and 3D 
processing scripts and then analyzed in NMRViewJ (One Moon Scientific). 
Backbone assignments were deposited in the BMRB (i.d.-27061). 
NMR Titrations: The change of crosspeak locations during a titration was 
monitored with a 2d 1H-15N HSQC-TROSY pulse sequence and with a sample 
containing 100 μM [2H,15N]-holo-ACPP, 25 mM MOPS, 100 mM sodium chloride, 
1 mM dithiothreitol, 10 mM magnesium chloride, 1 mM DSS, 5% 2H2O, pH 7.1. 
The total protein concentration in the NMR tube was quantified at each point by 
measuring A280 (εACPP= 1490 M-1 cm-1; εACPS= 17990 M-1 cm-1). The titration 
included the following concentrations: 0, 21.7, 39.8, 55.9, 77.7, 89.2, 101.2, 
142.1 μM ACPS and 100, 92.2, 85.8, 80.3, 75.4, 71.1, 62.0, 52.3 μM holo-ACPP, 
respectively.  
RDC Measurements: [2H,15N]-holo-ACPP and ACPS were mixed in a 1.1:1 
molar ratio and purified over the Superdex 200 column in the same manner as 
described above. Complex was concentrated using a 3 kDa cutoff filter unit. The 
NMR sample contained 335 μM each of holo-ACPP and ACPS monomer, 1 mM 
DSS, 10% 2H2O in the following buffer: 25 mM MOPS, 100 mM sodium chloride, 
1 mM dithiothreitol, 10 mM magnesium chloride, pH 7.1. An aligned sample was 
obtained by adding Pf1 phage (Asla Biotech) to a final concentration of 12.2 
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mg/mL (each monomer was reduced to 260 μM). (1JN-HN)iso and (1JN-HN+D)align 
measurements were obtained using a J-modulated HSQC-TROSY pulse 
sequence [28] set to collect 64 scans/FID and total 128 points. Spectra were 
collected with a recycle delay of 3 s and J evolution period of 0.5, 2, 4, 5.4, 7, 9 
or 10.8 ms. (1JN-HN)iso and (1JN-HN+1D)align values were determined by fitting 
decaying cosine functions in NMRViewJ. RDCs were calculated from (1JN-
HN+D)align - (1JN-HN)iso and fitted using PALES [29] and REDCAT [30]. From 47 
holo-ACPP cross peaks visible in a 1H-15N HSQC-TROSY spectrum, 30 provided 
high quality 1JHN-N-modulation data. Of these, 7 were removed due to locations in 
loop regions or as a result of poor fits to the model (18,22,33,45,56,64,69) 
(Figure 5-6B). The 23 RDCs used are for residues 4,7,8,10,12,14,16,19,23-
25,27-28,50-52,68,70-75. Residues 4-19 belong to a helix, 23-25 and 27-28 are 
on a loop region, 50-52 are at the base of a helix, and 68-75 belong to the c-
terminal helix.  
ITC Titrations: ACPS or holo-ACPP exchanged into a buffer containing 25 mM 
MOPS, 100 mM sodium chloride, 1 mM dithiothreitol, 10 mM magnesium 
chloride, pH 7.1 using a Superdex 75 or G25 column, respectively. ACPS (220 μl 
of 86.3 μM) was placed in the sample cell of the MicroCal ITC200 (GE Life 
Sciences). Holo-ACPP (40 μl of 980 μM) was injected with 28 total injections 
(1x0.2 μl, 4x0.5 μl, 14x1 μl, 5x2 μl, and 4x3 μl) with a cell temperature of 25 °C, 
reference power=1, initial delay of 60 s, and stirring speed of 1000 rpm. There 
was a 120 s delay between the 0.2, 0.5, and 1 μl injections and 180 s delay 
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between the 2 and 3 μl injections. Isotherms were analyzed using the CHASM 
ITC data analysis program [31,32]. 
Results 
Holo-ACPP binding by ACPS- 
Holo-ACPP bound ACPS with surprisingly high affinity (Figure 5-2 and S2).  
 
Figure 5-2. Holo-ACPP binding by ACPS reveals negative cooperativity. A. 
Heat change upon each injection (volume indicated) observed during a titration 
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as monitored by isothermal titration calorimetry. B. The binding isotherm derived 
from integrating peaks in (A) demonstrates two independent binding events. An 
independent experiment is shown in Figure S5-2. 
If we assume 3:3 stoichiometry in the complex, the ratio of N values from ITC 
(relative to 1 ACPS trimer) of 0.18 and 0.57 indicate two independent binding 
events with an approximate binding stoichiometry of 2:1. One holo-ACPP binds 
with a KD = 55 nM followed by the final two holo-ACPPs which bind with an 
indistinguishable KD = 1 μM (Table 5-1).  
Table 5-1. 
Run #1 Run #2 
Event #1  Event #1  
N 0.18 N 0.14 
KD 55.2 ± 51.9 nM KD 45.5 ± 95.0 nM 
ΔG -41.4 ± 38.9 kJ mol-1 ΔG -41.9 ± 87.6 kJ mol-1 
ΔH -23.0 ± 1.7 kJ mol-1 ΔH -25.9 ± 1.7 kJ mol-1 
ΔS 61.7 ± 58.1 J mol-1 K-1  ΔS 53.5 ± 111.9 J mol-1 K-1 
Event #2  Event #2  
N 0.57 N 0.53 
KD 1.0 ± 0.3 μM KD 1.25 ± 0.5 μM 
ΔG -34.2 ± 10.9 kJ mol-1 ΔG -33.7 ± 13.5 kJ mol-1 
ΔH -33.5 ± 1.7 kJ mol-1 ΔH -33.9 ± 5.4 kJ mol-1 
ΔS 2.5 ± 0.8 J mol-1 K-1 ΔS -0.7 ± 0.3 J mol-1 K-1 
 
These data are consistent with negative cooperativity: binding one holo-ACPP 
molecule to the ACPS trimer reduces affinity by ~20-fold for the next two holo-
ACPP molecules. The two binding events are marked by a free energy difference 
of 7.4 kJ/mol (-41.4 kJ/mol and -34 kJ/mol for each event) and also a significant 
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difference in entropy (61.7 J mol-1 K-1 and 2.5 J mol-1 K-1 for the first and second 
events). Positive entropy coupled with a –ΔG and –ΔH are consistent with a 
model of stabilizing hydrogen bonds and an unfavorable conformational change. 
These data suggest there is both high affinity and negative cooperativity in 
product binding.  
X-ray crystallography of ACPS- 
Crystallization of the holo-ACPP:ACPS complex yielded both rod and plate 
crystal forms. The plate crystals diffracted to 1.6 Å. Molecular replacement with a 
Bacillus subtilis ACPS model (pdb=1F7T;[14]) revealed initial phases and the 
presence of only one ACPS enzyme in the asymmetric unit, a finding confirmed 
with MALDI-TOF-MS analysis of the plate crystals (data not shown). It is likely 
the high salt concentration in the crystallization condition (~2.0 M sodium 
formate/nitrate) separated the holo-ACPP:ACPS complex.  
Diffraction data from the plate crystals were of high completeness and 
quality to 1.85 Å and used to solve a model of unliganded E. coli ACPS (Table 5-
2). ACPS forms a trimer with a central nine-strand beta-barrel (3 per monomer) 
observed in other ACPS crystal structures (Figure 5-3A) [14,15,17]. Electron 
density at the active site residues and catalytic magnesium ion is shown in Fig 5-
3C. There are differences in secondary structure position and orientation 
between E. coli, Bacillus subtilis and Neisseria meningitidis structures (Fig S5-5). 
The main helix from residues 46-64 shifts 6.5 Å from the N. meningitidis to the E. 
coli/B. subtilis structures. 
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Table 5-2. 
 
Data collection 
 
ACPS 
holo-ACPP:ACPS 
complex 
Space group C2 P43 
Cell dimensions   
a, b, c (Å) 100.376, 69.522, 
59.894 
251.424, 251.424, 
58.939 
α, β, γ (°) 90, 109.55, 90 90, 90, 90 
Resolution (Å) 29.6-1.604 49.31-3.85 
No. Datasets 1 3 
Rmerge 0.1458 (2.368)* 0.254 (1.968) 
I/δI 7.85 (0.28) 4.6 (0.7) 
CC1/2 0.995 (0.0801) 0.989 (0.085) 
Completeness (%) 98.0 (82.0) 93.7 (71.6) 
Redundancy 3.8 (2.1) 5.6 (3.7) 
Unique Reflections 32448 (2704) 31881 (3464) 
   
Refinement   
Resolution 29.6-1.85 49.19-3.85 
Rwork/Rfree 0.209/0.211 0.307/0.313 
No. atoms 3200 23714 
     Protein 2956 23633 
     Ligand/ion 44 81 
     Water 200 n.a. 
B-factors 35.44 82.59 
Protein (Å2) 34.99 n.a. 
Ligand/ion (Å2) 44.93 n.a. 
R.m.s deviations   
     Bond lengths (Å) 0.021 0.019 
     Bond angles (°) 2.170 1.680 
PDB i.d. 5VBX 5VCB 
 
*values in parentheses refer to the outer shell 
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Figure 5-3. The structure of E. coli ACPS solved to 1.85 Å. A. The ACPS 
backbone (green ribbons) as viewed down the 3-fold symmetry axis, Mg2+ ions at 
the active site are shown as red spheres. B. An overlay of chain A (green), B 
(blue) and C (red) highlight conformational heterogeneity that is largely limited to 
residues 65-94. C. Electron density (scaled to 1.5 σ) showing the ACPS active 
site with Asp9, Glu58 and the coordinated magnesium ion. Waters are shown as 
blue spheres (EDO = ethylene glycol). 
There is also a difference of 5 Å on the helix from residues 12-24. These are 
significant deviations in secondary structure position within structures that have 
very close agreement of the central 9 antiparallel beta strands. In general there 
are significant differences in orientation of the 3 helix bundle from residues 13-
43. The ACPS structure is well defined with the exception of residues 64-69 that 
form a loop and different conformations in the ACPS trimer (Fig 5-3B). These 
residues also showed high isotropic B values (>90). It is not surprising that this 
loop is mobile as it sits at the ACPP binding interface and likely reorients to 
accommodate binding.  
X-ray crystallography of the holo-ACPP:ACPS complex- 
MALDI-TOF-MS indicated the presence of both holo-ACPP and ACPS in the rod-
shaped crystals that diffracted to 3.5 Å and had a much larger asymmetric unit 
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(Table 5-2). Analysis of the diffraction data with a Pearson correlation coefficient 
(CC1/2) and a student’s t-test (p<0.01) indicated near complete and reliable data 
to 3.85 Å [33,34,35]. Molecular replacement with the Bacillus subtilis holo-
ACPP:ACPS complex was unsuccessful, and not surprising given the low 
resolution data and lack of sequence identity (38 %). We utilized an iterative 
method to sequentially build the asymmetric unit with E. coli ACPS structure 
determined above. After determining the location of four ACPS trimers, five holo-
ACPP monomers were fitted. The remaining seven ACPP molecules were fit 
using rigid body placement and the previously fit ACPs as a guide. Only at this 
stage was clear density for the final holo-ACPP:ACPS hexamer visible revealing 
an asymmetric unit that contained 15 holo-ACPP and 15 ACPS monomers 
arranged into five hexamers (Figure 5-4A). Electron density maps showed very 
clear secondary structure elements and some side chain definition (Figure 5-4B). 
Electron density near Ser36 on several ACPP molecules could not be accounted 
for by polypeptide atoms and was modeled with atoms of the 
phosphopantetheine moiety (Figure 5-4C). This model is similar to a model of the 
holo-ACPP:ACPS complex from B. subtilis though some differences are evident, 
including the placement of ACPP molecules that are closer to the ACPS in the E. 
coli complex (Figure 5-4D). 
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Figure 5-4. Structure of the E. coli holo-ACPP/ACPS complex solved to 3.85 
Å. A. The asymmetric unit contained 5 hexameric holo-ACPP/ACPS complexes. 
One hexamer is highlighted with a black outline. B. Electron density (scaled to 
1.25 σ) shows the clear resolution of ACPS polypeptide features in green and C. 
partial resolution of the pendant phosphopantetheine (PNS, orange stick model). 
Electron density corresponding to sidechain atoms was observed but sidechain 
models are not shown in this image. A comparison of the E. coli holo-
ACPP/ACPS complex (D1) is similar to a structure of the catalytically inactive 
apo-ACPP/ACPS complex from Bacillus subtilis (D2., PDB-1F80), though the E. 
coli holo-ACPP ligands are closer to the center of the complex than the apo-ACP 
from B. subtilis.  
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Identifying the ACPS binding interface of holo-ACPP- 
Analysis of the holo-ACPP:ACPS complex by solution NMR spectroscopy 
provided an independent analysis of the binding interface. Though ACPP is often 
used for NMR experiments [26][36,37,38], assignments of backbone heavy 
atoms are necessary to characterize binding interfaces and molecular orientation 
but are not available in the BioMagResBank (www.bmrb.wisc.edu) for holo-
ACPP. We assigned 100% of the HN, 98.7% N, 98.7% CA, 98.6% CB and 97.5% 
of CO resonances using standard triple-resonance experiments (Figure S5-4).  
Chemical shift perturbations of holo-ACPP upon ACPS titration identified a 
binding interface. Of 47 amide crosspeaks unambiguously identified in 1H-15N 
HSQC-TROSY spectra, those with large chemical shift perturbations clustered on 
one facet of ACPP, near Ser36, that was comparable to the interface observed 
by X-ray crystallography (Figure 5-5A-C). Multiple peaks disappeared during the 
titration, including many peaks at the core of the interface that correspond to 
atoms from the loop and helix around Ser36 (residues 30-47). 
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Figure 5-5. The holo-ACPP/ACPS interfaces identified by solution NMR 
spectroscopy and X-ray crystallography are compatible. A. Chemical shift 
perturbations of backbone holo-ACPP residues were measured following a 
titration with ACPS. Amide crosspeaks with significant (red lines: 0.2-1.0 ppm), 
moderate (yellow, 0.10-0.19 ppm), minimal (blue, <0.1 ppm) perturbation or 
crosspeaks broadened beyond the point of detection (vertical black line) are 
indicated and mapped onto a model of ACPP (B.). C. The holo-ACPP/ACPS 
interface residues identified through X-ray crystallography are shown as a red 
surface on ACPP. 
 
NMR measurement of holo-ACPP orientation in the complex- 
Symmetric oligomers with three or more subunits provide additional opportunities 
to characterize relative binding orientation by measuring residual dipolar 
couplings (RDCs) with a solution NMR spectroscopy approach [39,40]. It is 
known from RDCs of n ≥ 3 homo-oligomer that 1) the principle alignment tensor 
axis must be coincident with the molecular rotational symmetry axis, and 2) the 
alignment tensor will be axially symmetric (Rhombicity ~0) [40,41]. RDCs are 
expected to provide the orientation of holo-ACPP with respect to the ACPS 
molecular symmetry axis (the z axis), but this measurement does not report 
whether holo-ACPP is oriented along the + or - z axis (differing by a 180 degree 
rotation around the x or y axes), or what rotation each holo-ACPP experiences 
relative to ACPS (all rotations around the z axis are indistinguishable), respective 
to 1) and 2) above. The incorporation of additional RDCs collected with a unique 
alignment condition does not provide additional information.  
HSQC-TROSY-based experiments measured the 1JHN-N-modulation of 
amide nitrogen nuclei using the [2H,15N]-holo-ACPP:[unlabeled]ACPS complex in 
the presence (anisotropic) or absence (isotropic) of Pf1 phage [28,42]. 
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Subtracting coupling values obtained without phage (1JHN-N) from measurements 
with phage (1JHN-N+1D) provided RDC measurements. We fitted values from 23 
residues found in multiple ACPP helices to the X- ray model of the holo-
ACPP:ACPP hexamer  with a high quality of fit (Q = 0.17; Fig 5-6B) [43,44]. The 
analysis also revealed an axially symmetric alignment tensor (Rhombicity = 0.03) 
that was aligned with the z-axis when using models of the hexamer oriented with 
the molecular symmetry axis parallel to the z axis (Figure 5-6A)[44].  
 
Figure 5-6. The orientation of holo-ACPP relative to ACPS measured by 
residual dipolar couplings is indistinguishable from the orientation 
observed by X-ray crystallography. A. Sauson-Flamsteed plot shows the best-
fit alignment tensors and indicates axial symmetry of the ACPP protein in 
complex with ACPS. RDCs were fitted to the ACPP model from the holo-
ACPP:ACPS complex determined by X-ray crystallography after the rotational 
symmetry axis of the heterohexamer was rotated to be parallel to the z-axis. B. A 
plot comparing the measured RDCs with RDCs calculated following the best fit of 
the alignment tensors. (Bars represent the sum of fitted J and J+D errors for each 
RDC). 
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As expected, orientation of holo-ACPP along either the + or - z axis along with all 
possible rotations around z yielded the same quality of RDC fit. This degeneracy 
was resolved by analyzing how each possible holo-ACPP orientation matched 
the interface identified by NMR and if Ser36 was brought within close proximity of 
the ACPS catalytic residues leaving only one likely orientation that was 
indistinguishable from the orientation observed by X-ray crystallography. In 
conclusion, the solution NMR data and X-ray crystallography model 
unambiguously define the holo-ACPP:ACPS interface and relative orientation. 
Discussion 
We characterized the E. coli ACPS in apo and holo-ACPP-bound forms 
using multiple techniques. A model of the apo ACPS solved by X-ray 
crystallography showed many similarities in secondary structure to previously 
solved models [14,17,45] though some differences were noted. We also 
determined the structure of the holo-ACPP:ACPS complex with ACPS and 
validated the model using solution NMR spectroscopy. These data clearly identify 
the ACPP/ACPS interface and relative orientations in the 3:3 oligomer. 
This solution and solid state characterization of ACPS clearly indicate a 
trimeric stoichiometry and ability to bind three holo-ACPP products. It is not clear 
why previous efforts identified ACPS dimer forms in solution [18,19,20]. We 
found no evidence of smaller ACPS oligomers in gel filtration chromatography 
experiments, though it is possible that ACPS at lower concentrations forms 
monomers or homodimers (data not shown). 
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It is surprising that ACPS has such strong affinity for product, but previous 
studies claiming the observation of substrate inhibition could have been 
misinterpreted product inhibition [18,20]. Our binding data clearly shows negative 
cooperativity with a second binding event having a KD of 1 μM, the same value 
reported previously for ACPP KM. Product inhibition would seem more 
mechanistically likely as ACPP should not bind ACPS until after CoA binding as 
reported (however, the crystal structure of this ACPS-ACPP complex was 
catalytically dead) [14]. The strong binding of holo-ACPP to ACPS is facilitated 
by strong charge-charge interactions given the disparate calculated isoelectric 
points (4.0 and 9.3, respectively). There are several aspartates and glutamates 
on holo-ACPP and contribute to the interface, being located near arginines and 
lysines on ACPS. The loop from residues 64-74 and turn from 82-85 on the apo-
ACPS show the most conformational heterogeneity and in the case of the loop, 
high B factors and low side chain occupancy (Figure 5-3B and Figure 5-7). These 
two regions are located at the binding site of holo-ACPP likely deform to 
accommodate ACP binding. Loop orientations as well as secondary structure 
motifs of ACPS that differ in the apo and complex structures support this 
observation. ACPS residues 65-94 make an intimate connection with holo-ACPP 
to form a contiguous “belt” around the enzyme. This belt is poised to serve as a 
conduit to transmit the status of single holo-ACPP binding to the other two holo-
ACPP binding sites and may mediate the observed negative cooperativity with 
respect to holo-ACPP binding. This type of negative feedback inhibition may act 
as a checkpoint in fatty acid biosynthesis. 
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Figure 5-7. Allosteric binding model representing negative cooperativity in 
holo-ACPP binding by ACPS. Holo-ACP synthase is shown in green with a 
“belt” of residues (65-94) in red. 
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Cellular coenzyme A levels are tightly controlled and regulated in multiple 
manners [46,47,48,49]. Inhibiting ACPS activity would prevent unnecessary 
coenzyme A degradation and holo-ACPP production. 
There are significant differences between the ACPS enzyme from humans 
and E. coli. The most notable difference is the human ACPS is a single 
polypeptide that folds into an intramolecular dimer [15]. A 10 amino acid 
expansion from the human enzyme is present in the region of residues 82-85 on 
the E. coli enzyme which is part of the belt proposed to impart negative 
cooperativity. This is important as the loop expansion in the human enzyme 
takes up the space where a third ACPS molecule would bind ensuring the 
intramolecular dimer and not a trimer is the active unit. The loop from 62-73 on 
the E. coli enzyme that interacts with ACPP deviates by ~5-15 Å when compared 
to the human enzyme. Residues from 81-85 on the E. coli enzyme involved in 
ACP binding are very different from those in the human enzyme, NDELG vs 
RTAKGKP. There are also two potential salt bridges formed between Asp38 and 
Glu41 on holo-ACPP and Arg15 and Arg22 on ACPS in the E. coli enzyme that 
are not present in the human enzyme. These key differences could allow for the 
generation of highly specific inhibitors of the E. coli enzyme that would not have 
any effect on the human enzyme. 
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Figure S5-1. Gel filtration and MALDI-TOF-MS of the ACPP:ACPS complex. 
A. The ACPP:ACPS complex elutes from a Superdex 200 column in a single 
peak. Fractions are marked with vertical lines; the void column of the column, 
measured with blue dextran, is indicated with a solid blue vertical line. B. 
Analysis of the ACPP:ACPS complex by MALDI-TOF-MS reveals both a high 
proportion of holo-ACP. 
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Figure S5-2. ITC replicate 2. 
A direct replicate of the experiment shown in Figure 5-2 with all parameters in 
close agreement. 
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Figure S5-3. Blank Titration 
Blank titration of holo-ACP into buffer, very low responses were observed.  
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Figure S5-4. Assignment Strips for holo-ACP 
2D strips from triple resonance assignments for C-terminus residues 59-77 of 
holo-ACP. 
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Figure S5-5. 
Alignments of the ACPS crystal structures from E. coli, B. subtilis and N. 
meningitidis. Shows the differences in secondary structure orientations present 
within the same overall fold of the enzyme. 
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